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1 Introduction 
1.1 The role of autophagy and apoptosis for neuronal survival and death 
Autophagy and apoptosis play major roles in determining the cellular fate. Accordingly, 
they participate in development, cellular homeostasis, and both in physiological as well 
as in pathological processes [1]. Apoptosis is executed by activated caspases, which are 
specific enzymes that participate in signaling cascades that culminate in the rapid 
removal of organelles and other cellular structures [2]. Autophagy is a highly conserved 
cytoprotective process whereby cytoplasmic contents are sequestered, transported via 
double-membrane autophagosomes to lysosomes, and degraded [3]. 
Along with regulated necrosis and other forms of programmed cell death [4], 
pathological mechanisms of autophagy and apoptosis have been detected in 
neurodegenerative diseases, such as Parkinson’s disease (PD) or Alzheimer’s disease 
(AD) and acute brain injuries [5]. 
 
1.1.1 Autophagy 
The term autophagy, coined from the greek words of αυτς (‘autos’, self) and φαγειν 
(‘phagein’, eating), was first described by Christian de Duve in 1963 as a lysosome-
mediated degradation process for non-essential or damaged cellular constituents [6]. 
Autophagy is a generic term for all pathways by which cytoplasmic materials are 
delivered to the lysosome or the vacuole in animal cells or plants [3]. In contrast to the 
ubiquitin-proteasome system (UPS), which serves as the primary route for degradation 
for thousands of short-lived proteins [7], autophagy is primarily responsible for 
degrading long-lived proteins and organelles. Recent studies indicated that there is a 
coordinated and complementary relationship between these two systems. Inhibition of 
proteasomal activities has been previously shown to induce autophagy [8]. In contrast, it 
was also described that proteasomes were activated in response to pharmacological 
inhibition of autophagy [9]. 
When autophagy was discovered over 50 years ago it was assumed to represent a 
general non-selective degradation pathway activated by nutrient limitation. Since then 
autophagy has been linked to human pathophysiology, including cancer, 
neurodegeneration, immune response and ageing [10]. 
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In 1992, Yoshinori Ohsumi and his colleagues at the University of Tokyo discovered 
that autophagy also occurs in yeast. Being able to use yeasts as an experimental model 
opened the door for studying the molecular biology of the autophagic machinery [11]. 
Today, research on autophagy is a continuously growing field with increasing 
prominence because understanding the basic mechanisms of autophagy could lead to the 
development of new strategies for the treatment of various diseases, including 
neurological diseases. 
 
1.1.1.1 Forms of autophagy 
There are at least three types of autophagy, including macroautophagy, microautophagy 
and chaperone-mediated autophagy (CMA). They differ in terms of their mechanism for 
directing the cytoplasmic content to the lysosomes, where the engulfed content is 
degraded by lysosomal proteases into macromolecules and are released back into the 
cytoplasm [12, 13]. 
Macroautophagy is thought to be the major form of autophagy and it has been studied 
most extensively compared to the other classes. In this thesis I investigated 
macroautophagy, which I will hereafter refer to as autophagy. The initial step of 
autophagy is the elongation of isolated membranes surrounding cytoplasmic material, 
which forms a double-membrane structure, the autophagosome. Afterwards the 
autophagosome fuses with the lysosome, thereby generating the autophagolysosome, 
where their contents are degraded by lysosomal hydrolases [3, 14]. Recent studies 
revealed that post-translational modifications, in particular ubiquitination of 
macroautophagy regulators, lead to a selective degradation of certain cytoplasmic 
components such as protein aggregates, organelles, and intracellular pathogens [15–17]. 
Another post-translational modification demonstrated to facilitate selective targeting of 
cargo for macroautophagy is acetylation [18]. 
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Figure 1. Main steps of macroautophagy. The main steps of the macroautophagy process are induction, 
autophagosome formation, sequestration and degradation. Autophagy induction involves the 
sequestration of portions of the cytoplasm, including organelles, within a double-membrane autophagic 
vacuole, named autophagosome. The autophagosome undergoes fusion with a lysosome to form an 
autophagolysosome, in which hydrolases degrade the cytoplasmic material [19]. 
 
During microautophagy, tiny portions of cytoplasm are directly sequestered and 
subsequently engulfed by lysosomes. In the past two decades, the growth in the 
understanding of microautophagic processes has come about almost entirely from 
studies performed in yeast. By contrast, few investigators have studied microautophagy 
in mammalian cells as a primary focus, and consequently the understanding has 
remained limited [20]. Chaperone-mediated autophagy, a selective form of 
autophagy, has only been identified in mammalian cells so far. Proteins degraded by 
CMA are identified individually by a cytosolic chaperone that delivers them to the 
surface of the lysosomes. There, the substrate proteins unfold and cross the lysosomal 
membrane. All the proteins internalized into lysosomes through CMA contain a 
pentapeptide motif (KFERQ) in their amino acid sequence that is essential for their 
targeting to lysosomes. These proteins are taken up by a complex, formed by the 
chaperone protein (hsc70) and co-chaperones (hip, hop, hsp40, hsp90, and bag1), 
directing them to a lysosome. At the lysosomal membrane the proteins are recognized 
by the LAMP-2A receptor that mediates their internalization into the lysosome [21]. 
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1.1.1.2 Physiological and pathophysiological role of autophagy 
Under physiological conditions, the process of autophagy occurs constantly. However, 
autophagic activity increases in conditions of cellular stress, such as starvation, hypoxia, 
drug treatment or exposure to radiation [22]. Autophagic activity is essential for various 
physiological processes, including cell survival, cell metabolism, development, aging 
and immunity [3]. Autophagy is generally considered to support cellular homeostasis 
and survival, but massive accumulation autophagosomes may represent either an 
alternative pathway of cell death (autophagic cell death) or an ultimate attempt of stress 
adaption [19]. More recent studies established a link between autophagy and disease. 
For example, macroautophagy deregulation at distinct steps including autophagosome 
nucleation, maturation and degradation has been demonstrated in many diseases such as 
neurodegenerative disorders, cancers and inflammatory disorders [12, 23, 24]. 
 
1.1.1.3 Autophagy in neurons 
Autophagy in neurons was controversially debated for a long time based on the pre-
conception that autophagy was only activated during nutrient deprivation and it was a 
general assumption that the brain was protected from such stress. Growing evidence 
however supports now that not only autophagy occurs naturally in neurons under 
physiological conditions, but that proper functioning of this catabolic pathway is 
required for function and maintenance of neuronal cells [25]. In the long run, autophagy 
is essential for neuronal health, while insufficient autophagy appears to be a 
contributing factor in chronic neurodegenerative diseases. For example, knockout mice 
lacking key mediator proteins regulating autophagy, such as Atg5 or Atg7 rapidly 
develop symptoms of neurodegenerative diseases with the presence of polyubiquitinated 
proteins in neurons as inclusion bodies [26, 27]. Moreover, basal autophagy is essential 
for maintaining axon homeostasis and morphology, and impaired autophagy results in 
axonal swelling, followed by progressive neurodegeneration [28, 29]. In 
neurodegenerative disorders, incomplete macroautophagic engulfment of cytosolic 
contents and mitochondria were observed in experimental models of Huntington's 
disease (HD) [30] and Parkinson's disease (PD) [31, 32], respectively, whereas in 
models of Alzheimer’s disease (AD) defects in autophagosome degradation were 
reported [33]. 
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1.1.1.4 Molecular mechanisms of autophagy 
Multiple autophagic proteins (Atg-proteins) that were discovered in the 1990s during 
genetic investigations in yeast regulate the autophagic process. In total, 35 Atg-proteins 
were discovered. Atg 1-10, 12-14, 16 and 18 are the so-called core Atg-proteins [34]. 
These core Atg-proteins are highly conserved in other eukaryotes and they act in a 
similar manner in yeast and mammalian cells [35, 36]. The biogenesis of 
autophagosomes is initiated with the formation of a pre-autophagosome (or 
phagophore), a membranous structure that contains all the proteins required for the 
creation of an autophagosome and that are assembled from membranes of preexisting 
organelles (endoplasmic reticulum, Golgi, mitochondria, plasma membrane) [37–40]. 
Induction of autophagy is initiated by the activation of the autophagy related gene-1 
(Atg1) complex, comprising Atg1, Atg13 and Atg17, as well as accessory proteins [41]. 
After this, vesicle nucleation requires activation of the class-III phosphatidylinositol-3-
kinase (Vps34) and Beclin-1/Atg6, as well as several other factors to recruit proteins 
and lipids for autophagosome formation. Vesicle elongation and completion are 
mediated by two-ubiquitin-like systems; Atg7 (E1-like) and Atg3 (E2-like) regulate the 
lipid modification (phosphatidylethanolamine, PE) of microtubule- associated protein 
light chain 3 (LC3, the mammalian orthologue of Atg8), which requires initial cleavage 
of LC3 by Atg4 protease; Atg7 and Atg10 (E2-like) regulate the conjugation of Atg12 
to Atg5, followed by transfer to Atg16. The Atg12/Atg5/Atg16 complex mediates LC3-
PE binding to the autophagosome membrane [42–44]. The fully assembled 
autophagosome is transported to the lysosome where the membranes fuse, resulting in 
breakdown of the autophagosome contents by the lysosomal enzymes [3, 41]. 
Furthermore, the Atg proteins LC3 (Atg8), Beclin-1 (Atg6) and Atg5 are well 
established markers for monitoring the autophagic process [45].  
Microtubule-associated protein light chain 3 (LC3) is the most widely monitored 
autophagy-related protein and exists in two forms, LC3-I (16 kDa) and its lipidated 
form LC3-II (14 kDa), which are localized in the cytosol and in autophagosomal 
membranes respectively. The expression level of LC3-II can be used to estimate the 
abundance of autophagosomes before they are degraded by lysosomal hydrolases. The 
subcellular localization of LC3 redistributes from a cytosolic diffuse pattern to 
punctuate staining in vacuolar membranes when autophagy is induced [19, 46].  
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Beclin-1 is the mammalian orthologue of yeast Atg6 and belongs to the class III 
phosphatidylinositol-3-kinase (PI3K) complex that participates in autophagosome 
formation. Beclin-1 has also been described as a B-cell lymphoma 2 (Bcl-2)-interacting 
protein. The ablation of autophagy by Bcl-2 is dependent on Beclin-1-Bcl-2 interaction. 
Dissociation of Bcl-2 from Beclin-1 leads to an induction of autophagy [47]. 
Atg5 is an E3 ubiquitin ligase which is necessary for autophagosome elongation [48]. 
Atg5 is activated by Atg7 and forms a complex with Atg 12 and Atg16L1. This 
complex is necessary for LC3-I conjugation to phosphatidylethanolamine (PE) to form 
LC3-II [49]. 
 
1.1.1.5 Major signaling pathways of autophagy upstream of the Atg machinery 
The central player in autophagic signaling is the mammalian target of rapamycin 
(mTOR), which negatively regulates autophagy.  
In mammals, mTOR can be included into two different complexes [50], mTORC1 and 
mTORC2. Both complexes display distinct cellular functions and phosphorylate 
different downstream targets [51]. The activity of mTORC1 is regulated via many 
signals including growth factors, insulin, nutrients, and cells stressors such as hypoxia, 
ROS and viral infections [52]. The two major pathways that regulate mTOR in 
mammalian cells are the PI3K/Akt and AMP-activated protein kinase (AMPK) 
pathways.  
The PI3K/Akt pathway is triggered by the binding of insulin or growth factors to its 
receptor, thereby activating class I phosphatidylinosital-3 kinase (PI3K). Activated PI3K 
converts PIP2 to PIP3 to activate Akt [53]. Akt then phosphorylates and inactivates the 
tuberous sclerosis complex 1/2 (TSC1/2) resulting in activation of Rheb and mTORC1, 
thereby inhibiting autophagy.  
The mammalian target of rapamycin can also sense changes in the cellular energy via 
AMPK. The activity of AMPK is required for autophagy to be induced in response to 
starvation in mammalian cells [54]. Activation of AMPK inhibits mTORC1 dependent 
signaling by interfering with the activity of Rheb, which leads to induction of 
autophagy.  
Although the suppression of the mTOR is a major signaling pathway regulating 
autophagy, autophagy can also be activated independent of mTOR by various stimuli, 
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such as through altering macroautophagy genes transcription or by reducing the cellular 
level of inositol 1,4,5-trisphosphate (IP3) [55, 56]. 
 
 
Figure 2. Major pathways that regulate mTORC1 in mammalian cells. The mTOR signaling pathway 
can receive input from growth factors and insulin via class I PI3K, which activates Akt/PKB. In turn, Akt 
activates mTORC1 via the inhibition of TSC 1/2 and Rheb, leading to inhibition of autophagy. AMPK, 
which is activated when the AMP/ATP ratio increases, inactivates mTORC1 by activating TSC2, 
resulting in autophagy induction [57]. 
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1.1.1.6 Activation of autophagic activity 
The most frequently investigated physiological stimulus of autophagy is nutrient 
starvation [58]. But autophagy is also induced by physiological stimuli, such as growth 
factors and hormones, as well as by pathogen invasion. Moreover, reactive oxygen 
species (ROS) can be involved in this process [59]. Another approach to activate 
autophagy in experimental setups is through the modulation of nutrient-sensing 
signaling pathways. Further, rapamycin, an inhibitor of mTOR, and its analogs activate 
autophagy both in vitro and in vivo [60]. Starvation and mTOR inhibition affect a wide 
range of cellular responses, e.g. at the levels of protein synthesis and cellular 
metabolism, in addition to autophagy activation. Several mTOR independent autophagy 
inducers have also been reported. For example Lithium [61], BH3 mimetics [62], 
trehalose or small molecule enhancers of rapamycin (SMERs) [63, 64]. These 
substances also lack specificity for the autophagy process and may further induce 
various unrelated cell responses. 
 
1.1.1.7 Inhibition of autophagic activity 
Several pharmacological inhibitors are available and genetic manipulation techniques 
have also provided powerful tools to inhibit autophagic activity [65]. One of the most 
commonly applied pharmacological approaches to inhibit autophagy in vitro involves 
the use of PI3-kinase inhibitors, such as wortmannin, LY294002 or 3-Methyladenine (3-
MA) [66–68]. All of these substances inhibit both class I PI3K activity (which inhibits 
autophagy) as well as class III PI3K activity (which is required for autophagy) [69]. As 
PI3-kinases regulate multiple diverse cell signaling and membrane trafficking processes, 
these PI3-inhibitors are not specific for inhibition of autophagy. Additionally, 3-MA, 
which is used at very high concentrations, can target other kinases and affect other 
cellular processes, such as glycogen metabolism, lysosomal acidification [70], 
endocytosis [71] and the mitochondrial permeability transition [72]. 3-MA can suppress 
proteolysis even in Atg5-deficient cells, suggesting that its effects on protein 
degradation extend beyond its role in autophagy inhibition [48]. Other pharmacological 
inhibitors of autophagy block later stages of the process. Microtubule-disrupting agents 
(e.g. vinblastine) inhibit autophagosome-lysosome fusion [73, 74]. Final degradation of 
autophagic cargo inside autolysosomes can also be inhibited by ammonium chloride, 
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bafilomycin A1, chloroquine, and lysosomal protease inhibitors such as E64d and 
pepstatin [75]. A major limitation of these substances is that they affect other cellular 
processes besides autophagy such as mitosis and endocytosis.  
Genetic approaches provide a more specific inhibition of autophagy. Autophagy 
deficiency or reduction has been confirmed in cells lacking Atg3 [76], Atg5 [48], 
Beclin-1 [77, 78], Atg 7 [79], Atg9a [80], Atg 16L [81, 82], FIP200 [83] and Ambra1 
[84]. However, it is important to note, that even the Atg-proteins may not be entirely 
specific for autophagy. In fact they may exert autophagy-independent functions, 
including roles in cell death signaling, endocytosis, and immunity-related GTPase 
trafficking [85, 86]. 
 
1.1.1.8 Autophagic cell death 
In many in vitro and in vivo systems cell death is often accompanied by features of 
autophagy. This led to the proposal of autophagic cell death [85, 87]. Autophagy is a 
pathway activated by cellular stress. Therefore it is not surprising that cells undergoing 
death after stress also show features of autophagy. This conundrum has led to some 
confusion in the literature where signs of autophagy in dying cells led to the 
interpretation that cells are in fact using autophagy as a death mechanism. In most 
known cases, autophagy constitutes a cytoprotective response activated by dying cells 
in the attempt to cope with stress, and its inhibition may thus accelerating, rather than 
preventing cell death [88]. However, there is accumulating evidence of a complex 
interplay between the apoptotic and autophagic machinery [1, 87]. First, autophagy has 
been shown to mediate physiological cell death in vivo, during the developmental 
program of Drosophila melanogaster [89]. Second, autophagy appears to be responsible 
for the death of some cancer cells in vitro [90, 91].  
It is important then to discriminate between whether autophagy is determining cell 
death, or whether autophagy is altering the dynamics of death signaling. Shen and 
Codogno [92] have proposed that the following three criteria should be met to define 
cell death by autophagy: (i) cell death occurs independent of apoptosis; (ii) there is an 
increase in autophagic flux, not simply an increase in autophagy markers [93, 94]; and 
(iii) that suppression of autophagy using genetic deletion or chemical inhibitors is able 
to prevent cell death. Accordingly, all cases of cell death that exhibit markers of 
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autophagy such as the lipidiation of LC3 or an increased degradation of autophagic 
substrates like sequestosome 1 (SQSTM1), but cannot be blocked by autophagy 
inhibition should not be classified as autophagic cell death. 
 
1.1.2 Apoptosis 
The term apoptosis, derived from greek words (ἀπό apo, "away from" and πτῶσις 
ptōsis, "falling"), was first used by Kerr, Wyllie, and Currie in 1972 to describe a 
morphologically distinct form of cell death, although certain components of the 
apoptosis concept had been explicitly described many years previously [95, 96]. 
Apoptosis has been recognized and accepted as a distinctive and important mode of 
“programmed” cell death, which involves the genetically determined elimination of 
cells. The physiological function is the replacement of senescent or excessive cells [97]. 
Furthermore, apoptosis has an essential function during the development of the nervous 
system by controlling synapses and removing excessive and unneeded neural cells [98]. 
Apoptosis also occurs as a defense mechanism such as in immune reactions or when 
cells are damaged by disease or noxious agents [99]. Apoptotic cells show characteristic 
DNA fragmentation, nuclear condensation, membrane blebbing and the formation of 
apoptotic bodies. These apoptotic bodies are then phagocytosed by neighboring cells 
without causing any inflammatory response and damage to the surrounding tissues [95]. 
Pathological pathways of apoptosis have been associated with a lot of 
neurodegenerative diseases, such as AD and PD and also with acute brain damage as 
after cerebral ischemia or traumatic brain injury [100].  
Apoptotic cell death can be divided into two biochemical cascades, described as the 
extrinsic and the intrinsic pathway.  
 
1.1.2.1 Extrinsic apoptosis 
The extrinsic pathway is induced by extracellular stress signals that are sensed and 
propagated by specific transmembrane receptors, the so-called death receptors [101, 
102]. Binding of lethal ligands, such as FAS/CD95 ligand (FASL/CD95L), tumor 
necrosis factor α (TNFα) and TNF (ligand) superfamily member 10 (TNFSF10) to 
various death receptors (i.e., FAS/CD95, TNFα-receptor 1 (TNFR1) and TRAIL 
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receptor (TRAILR)1–2, respectively) can initiate extrinsic apoptosis [101]. The 
activation of these death receptors leads to the activation of several caspases, including 
caspase-8 and caspase-3. In some cell types including lymphocytes (‘type I cells’) 
active caspase-8 directly catalyzes the proteolytic maturation of caspase-3, thereby 
triggering the executioner phase of caspase-dependent apoptosis in a mitochondria-
independent manner [103, 104]. In other cells such as hepatocytes and pancreatic B 
cells (‘type II cells’) [103, 104], caspase-8 mediates the proteolytic cleavage of BH3-
interacting domain death agonist (BID), leading to the generation of a mitochondria-
permeabilizing fragment (known as truncated BID, tBID) [105, 106]. While ‘type I 
cells’ undergo extrinsic apoptosis irrespective of any contribution by mitochondria, 
‘type II cells’ succumb from the activation of death receptors while showing signs of 
MOMP, including the dissipation of mitochondrial transmembrane potential (ΔΨm) and 
the release of toxic proteins that are normally retained within the mitochondrial 
intermembrane space (IMS) [107]. Among these, cytochrome C drives – together with 
the cytoplasmic adaptor protein APAF1 and dATP – the assembly of the apoptosome, 
another caspase-activating multiprotein complex [108]. 
 
1.1.2.2 Intrinsic apoptosis 
Intrinsic pathways of apoptosis are triggered by intracellular stress. The signaling 
cascades for intrinsic apoptosis are highly heterogeneous, but they are all linked to 
mitochondria-centered control mechanisms. Along with the propagation of pro-
apoptotic signaling cascades, anti-apoptotic mechanisms are also activated in an attempt 
to allow cells to cope with stress. Both, pro- and antiapoptotic signals converge at 
mitochondrial membranes, which become permeabilized when proapoptotic signals are 
more potent than antiapoptotic signals [107]. The permeabilization can start at the outer 
mitochondrial membrane (mitochondrial outer membrane permeabilization, MOMP) or 
at the inner mitochondrial membrane due to the opening. Irreversible MOMP affecting 
most mitochondria within a single cell has multiple lethal consequences: (i) the 
dissipation of the ΔΨm, with cessation of mitochondrial ATP synthesis and ΔΨm-
dependent transport activities; (ii) the release of toxic proteins from the intermembrane 
space (IMS) into the cytosol (apoptosis inducing factor (AIF), cytochrome C (CYTC), 
endonuclease G (ENDOG), SMAC/DIABLO (second mitochondria–derived activator 
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of caspase/direct IAP binding protein with low pI), OMI/HTRA2 (high temperature 
requirement protein A2)); and (iii) the inhibition of the respiratory chain (favored by the 
loss of CYTC), leading to ROS overproduction and hence activating a feed-forward 
circuit for the amplification of the apoptotic signal [107]. Upon MOMP, cytosolic 
CYTC forms a multi-protein complex with Apaf-1 (apoptosis protease- activating 
factor-1) and pro-caspase-9, the so-called apoptosome. The apoptosome catalyzes the 
activation of execution caspases including caspase-3, -6 and -7. These caspases induce 
the breakdown of the cellular framework through degradation of substrates like actin or 
by activation of caspase-activated deoxyribonuclease (CAD) [108, 109]. AIF and 
ENDOG relocate to the nucleus, where they mediate large-scale DNA fragmentation 
independently of caspases [110–112]. SMAC/DIABLO and OMI/HTRA2 inhibit the 
antiapoptotic function of several members of the inhibitor of apoptosis (IAP) family, 
thereby derepressing caspase activation [113, 114]. In addition, OMI/HTRA2 exerts 
caspase-independent pro-apoptotic effects [115, 116]. Caspase activation does not play 
a prominent role in stress-induced intrinsic apoptosis in vitro, as demonstrated by the 
fact that chemical and/or genetic inhibition of caspases rarely confers long-term 
cytoprotective effects [117, 118]. 
 
1.1.3 Regulated Necrosis 
Necrotic cell death is described for several physiological and pathophysiological 
settings, but it has also be suggested to contribute to embryonic development [119, 
120]. Characteristics of necrosis are mitochondrial swelling, depletion of ATP, massive 
calcium influx and cell membrane dysfunction accompanied by deregulation of the 
intracellular ion homeostasis. At later stages, hallmarks of necrosis are cell swelling, 
membrane lysis and inflammatory processes [121]. For a long time, necrosis has been 
considered as a merely accidental cell death mechanism and was defined by the absence 
of morphological traits of apoptosis or autophagy. But necrosis can also appear in a 
highly regulated manner through defined molecular signaling pathways that involve 
activation of receptor interacting protein (RIP) 1 and/or 3 [122]. The term ‘necroptosis’ 
has recently been used as a synonym of regulated necrosis, but it was originally 
introduced to define a specific cascade of regulated necrosis that is ignited by TNFR1 
ligation and can be inhibited by the RIP 1-targeting compound necrostatin-1 [123]. 
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1.2 Neural Stem Cells and Neurogenesis 
Stem cells exhibit two defining characteristics, the seemingly unlimited capacity for 
self-renewal through cell division and the capacity for generating specialized cell types 
through differentiation [124]. In contrast, progenitor cells are proliferative cells with a 
limited capacity for self-renewal and are often unipotent. They are more determined for 
differentiation into a specific cell type than stem cells. Stem and progenitor cells are 
found in various tissues of adult organisms and they act physiologically as a repair 
system [125]. 
In the brain, stem and progenitor cells are the origin of adult neurogenesis. The process 
of adult neurogenesis occurs throughout life in two restricted brain regions in mammals, 
the subgranular zone (SGZ) in the dentate gyrus of the hippocampus, where new dentate 
granule cells are generated; and the subventricular zone (SVZ) of the lateral ventricles, 
where new neurons are generated and then migrate through the rostral migratory stream 
(RMS) to the olfactory bulb to become interneurons [124]. Adult neurogenesis is a 
dynamic, finely tuned process and subject to modulation by various physiological, 
pathological, and pharmacological stimuli. Neurogenesis in other adult central nervous 
system (CNS) regions is generally believed to be very limited under normal 
physiological conditions but could be induced after injury [126].  
These findings demonstrated that neural stem and progenitor cells have the potential to 
compensate and recover neural functions after acute and chronic CNS diseases. Studies 
have also started to illustrate the functional impact of new neurons on the existing 
neural circuitry and their contributions to brain functions under both normal and disease 
states [127]. 
 
1.2.1 Transplantation of Stem cells or NPC for the treatment of acute or chronic 
neurodegenerative diseases 
Acute neurodegenerative diseases such as cerebral ischemia or stroke, and chronic 
neurodegenerative disorders (e.g. AD, PD, HD, ALS) are characterized by progressive 
dysfunction and death of neurons leading to the severe neurological impairments [5]. 
Currently available therapeutic options to treat patients suffering from acute or chronic 
neurodegenerative diseases are limited. Most of the presently available treatments are 
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symptomatic and not curative. Thus, new therapeutic options to prevent neuronal cell 
death and to repair damaged neuronal tissue are highly warranted.  
Therefore, stem cell-based therapeutic approaches, e.g. transplantation, hold much 
promise as potential novel treatments to restore brain function of patients that suffer 
from acute or chronic neurodegenerative diseases. Stem-cells and progenitor cells have 
the potential to perform neurorestorative processes like neurogenesis, angiogenesis and 
modulation of inflammation or trophic support, thus facilitating functional recovery and 
neuroprotection [128–131].  
 
Neural cell types can be generated from various cell types by using different 
approaches. The spectrum of available stem cells and progenitor cells is reaching from 
neural stem cells (NSCs), pluripotent stem cells (PSCs), direct conversion of 
differentiated cells into induced neural stem cells (iNSCs), induced neuronal cells 
(iNCs) from different cell types to mesenchymal stromal stem cells (MSCs) from 
various tissues, like bone marrow, cartilage, umbilical cord blood, adipose tissue, adult 
muscle or amniotic fluid [132]. Also induced pluripotent stem cells (iPSCs) 
reprogrammed from fibroblasts [133] or hair follicle cells [134] can be used for stem 
cell-based therapy in acute or chronic neurodegenerative diseases.  
 
Numerous studies have been performed studying effects of neural stem cells and 
progenitor cell transplantation in model systems of several neurodegenerative diseases. 
For example recent findings from studies in a model of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) toxicity in monkeys demonstrated that transplantation of 
human NSCs led to behavioral improvement [135, 136]. Further, Blurton et al. have 
shown in 2009 [137] that NSCs along with brain derived neurotrophic factor (BDNF) 
can ameliorate complex behavioral abnormalities associated with AD pathology in 
transgenic mice that express pathogenic forms of amyloid precursor protein, presenilin, 
and tau. In a rat model of cerebral ischemia, transplanted fetal hNSCs have not only 
shown migration towards the ischemic lesion, but also generated mature neuronal cells 
within the infarcted/injured striatum [138, 139]. A recent study by Chen et al. showed 
that direct injection of iPSCs into injured areas of rat cortex significantly decreased 
infarct size, improved motor function, attenuated inflammatory cytokines, and mediated 
neuroprotection after middle cerebral artery occlusion (MCAo) [140]. Most 
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intriguingly, also intravenous application of stem cells may serve as a suitable route of 
application for efficient replacement of damaged neurons in the brain tissue. For 
example, in a model of MG-132-induced cell death of dopaminergic neurons, bone 
marrow mesenchymal stem cells (BM-MSCs) injected intravenously 3 weeks after the 
initial damage at a dose of at a dose of 1 million cells, displayed high increment of 
dopamine levels in striatum [141].  
The innovative concept of stem cell therapy has also been translated to clinical 
applications. For example, several clinical trials have been performed in which adult 
stem cells (MSCs) were transplanted to stroke patients [142, 143] PD [144], or AD 
patients (www.clinicaltrials.gov). The studies showed that transplantation of MSCs is 
safe and leads to functional recovery. Moreover, NPCs derived from aborted fetal tissue 
were used in a clinical study investigating Cerebral Palsy (CP) in children confirming 
that NPC transplantation was safe and effective [145]. In addition to these studies, 
ReNeuron, a UK based company, is currently conducting a clinical trial with 
immortalized human NSCs in stroke patients (NCT01151124).  
In summary, stem cell transplantation is safe and led to behavioral improvement, 
functional recovery, generation of mature neuronal cells, decreased infarct size and 
attenuated inflammatory cytokines in various model systems of neurodegenerative 
diseases. 
Accordingly, stem cell based approaches may provide novel therapies especially for the 
treatment of PD, HD, AD or ALS, SCI and stroke [128, 129, 146]. It should be kept in 
mind, however that stem cell-based therapy still holds many risks. In particular, very 
little is known about long term side effects. Further, the exact mechanism of therapeutic 
effects observed after stem cell/progenitor cell transplantation into the brain still 
remains unclear.  
To explain the benefit after stem cell/ progenitor cell transplantations, several 
hypotheses were discussed in the literature. A commonly applied hypothesis for the 
therapeutic effects observed after stem cell transplantation is the replacement of injured 
tissue by the transplanted stem cells through differentiation of the engrafted cells into 
new neuronal cells [128, 147]. However, only very few cells survive after 
transplantation which makes this explanation rather unlikely [148–150]. Further, studies 
demonstrated that functional improvement after stem cell transplantation occurs rapidly 
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and is often detectable within one week of transplantation, which is an insufficient time 
period for the transplanted cells to become neurons and integrate successfully into the 
brain circuitry [151]. A more reasonable hypothesis is that interaction of stem/ 
progenitor cells with the host brain may lead to neuroprotective effects through the 
release of trophic factors or the stimulation of endogenous growth factor synthesis, 
which may contribute to recovery of functional impairments [152]. It is also known, that 
NSCs exert antioxidant properties thereby rescuing the surrounding neurons [153]. 
Moreover, enhanced angiogenesis, inhibition of apoptosis and stimulation of 
recruitment, proliferation and differentiation of endogenous stem cells that reside in the 
brain tissue are further hypotheses to explain the beneficial effects of stem cell and 
progenitor cell transplantation [154–156].  
 
1.2.1.1.1 Conditioned medium (CM) of stem cells or progenitor cells 
Because of the finding that most stem cells die after transplantation in vivo and that 
trophic support is likely responsible for the beneficial effect after transplantation rather 
than cell or tissue replacements, conditioned medium (CM) of dead or alive stem cells 
or progenitor cells was used in previous studies investigating neurodegenerative 
diseases. This CM reflects the properties of the surroundings of the stem cell/progenitor 
cell transplants. Furthermore, investigation of CM may provide a deeper understanding 
for the protective components and the mechanisms involved in neuroprotective effects 
after stem cell transplantation. Studies on several types of conditioned medium (CM) 
were already performed. A previous study showed that application of adult bone 
marrow stromal cells (BMSC) CM attenuated staurosporine (STS) or amyloid-beta 
peptide-induced apoptosis and triggered endogenous survival signaling pathways that 
mediate protection against apoptotic insults in primary embryonic rat neurons [154]. 
NSC-conditioned medium (NSC-CM) was neuroprotective in an in vitro model of HD 
with modulating mutant huntingtin-induced cytotoxicity [157]. Recently, a study 
demonstrated that factors present in mesenchymal stem cells conditioned medium 
(MSC-CM) improved migration of resident stem cells from human cardiac tissue [158]. 
In a study using MSCs [159], the derived CM displayed significantly elevated levels of 
VEGF, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory 
protein-1α (MIP-1α), MIP-1β and monokine induced by IFN-γ (MIG) compared to 
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control media. The MSC CM affected MSC migration, promoted angiogenesis and 
reduced apoptosis in H9c2 cells or canine jugular vein vascular endothelial cells 
(CVEC). Another study with human MSCs CM reported that MSCs secrete brain-
derived neurotrophic factor (BDNF) which promoted neuronal survival in cultured 
rodent cortical neurons against trophic factor withdrawal or nitric oxide (NO) exposure 
[160]. 
 
1.3 In-vitro model systems to investigate neuronal cell death 
1.3.1 Glutamate-induced oxidative stress in HT-22 cells 
In order to investigate mechanisms of neuronal cell death, the well-established 
immortalized mouse hippocampal cell line (HT-22) that is particularly sensitive to 
glutamate was used for this thesis. HT-22 neurons have been generated from HT-4 cells, 
a cell line originating from primary mouse hippocampal neurons. Immortalization of 
these neuronal cells has been achieved using a temperature-sensitive SV-40 T-antigen 
[161]. Glutamate is an important excitatory neurotransmitter in the central nervous 
system that is largely involved in regulating learning and memory at the level of 
dendritic spines. At high concentrations, however it is highly neurotoxic, excessive 
glutamate release is, for example, thought to be involved in the development of acute 
brain damage and chronic neurodegenerative diseases including PD and AD [162, 163]. 
The HT-22 cells applied in this study do not express ionotropic glutamate receptors 
[164] and are thus not susceptible to glutamate-induced rapid calcium influx and 
excitotoxicity. In this model system of glutamate toxicity, cell death is mediated via the 
competitive inhibition of xCT, a glutamate/cystine antiporter, which is required for the 
delivery of cystine into neuronal cells [165]. Inhibition of cystine uptake by high 
concentrations of extracellular glutamate leads to an imbalance in cellular cysteine 
homeostasis. Cysteine is required for the synthesis of the cellular antioxidant 
glutathione (GSH). After treatment of cells with glutamate, a gradual drop in 
glutathione levels is detected, followed by impaired activity of the 
glutathionperoxidase-4 (GPx4), excessive accumulation of ROS and cellular death 
[166]. Such excessive ROS formation occurs through an activation of 12/15 
lipoxygenases, which under physiological conditions are negatively regulated by GPx4. 
Downstream pathways of ROS accumulation include on the one hand the activation of 
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the proapoptotic BH-3 only protein Bid and on the other hand a direct effect on 
mitochondria, accompanied with the release of the AIF [167, 168]. In HT-22 cells, 
glutamate induces a form of programmed cell death with characteristics of both 
apoptosis and necrosis [169]. This kind of cell death has been termed oxytosis [170]. No 
significant caspase activation is observed during the development of glutamate-induced 
cell death [167]. 
 
 
Figure 3. Model of glutamate-induced cell death in HT-22 cells. Exposure to millimolar 
concentrations of glutamate leads to an inhibition of the xCT transporter which results in a depletion of 
cystine and cysteine in the cell. This is followed by a decrease in glutathione levels and causes a fall in 
Gpx4 activity. In response to these events ROS formation is increased which leads to the translocation of 
Bid to the mitochondria where activated Bid induces mitochondrial fragmentation and mitochondrial 
membrane permeabilization. Consequently, the pro-apoptotic factor AIF translocates from mitochondria 
to the nucleus and cleaves DNA, thereby executing cell death [168].  
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1.3.2 Excitotoxicity in Primary Cortical Neurons 
Primary cortical neurons were prepared from cortices of embryonic rats (E 16-18) 
(Sprague Dawley, Janvier) [171]. Besides the induction of oxidative stress in HT-22 
cells, glutamate is able to induce receptor-initiated excitotoxicity in primary neurons 
[172]. Excitotoxicity is defined as cell death resulting from the toxic actions of 
excitatory amino acids. Because glutamate is the major excitatory neurotransmitter in 
the mammalian CNS, neuronal excitotoxicity usually refers to the injury and death of 
neurons arising from prolonged exposure to glutamate and the associated excessive 
influx of ions into the cell [173]. In physiological conditions, glutamate is the major 
neurotransmitter in primary perception and cognition in the brain, producing an 
excitatory response. However, many studies linked excitotoxicity to a variety of 
neuropathological conditions, suggesting that several neurodegenerative diseases may 
share excitotoxicity as a common pathogenic pathway that triggers neuronal demise 
[174, 175]. Thus, understanding the pathways involved in excitotoxicity is of critical 
importance for potential future treatment strategies in many neurodegenerative diseases. 
The excitatory effects of glutamate are exerted via the activation of three major types of 
ionotropic receptors and several classes of metabotropic receptors linked to G- proteins. 
The major ionotropic receptors activated by glutamate are commonly referred to as the 
N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxy-5- methylisoxazole-4-
propionate (AMPA) and kainic acid (KA) receptors. These ionotropic receptors are 
ligand-gated ion channels permeable to various cations, predominantly Na
+
 and Ca
2+
 
[176]. Transient Ca
2+
-influxes triggered by these receptors lead to toxic disruption of 
the intracellular calcium homeostasis, increases in reactive oxygen species (ROS) and 
cell death. These detrimental downstream mechanisms include mitochondrial membrane 
depolarization, caspase activation, production of highly reactive oxygen (ROS) and 
nitrogen species (RNS), and cellular toxicity [177, 178]. 
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1.4 Aims of the thesis 
The aim of this thesis was to investigate the role of autophagy and apoptosis for 
neuronal resilience versus neuronal cell death in model systems of glutamate toxicity in 
vitro. Both mechanisms may play major roles in determining cellular survival or death. 
Accordingly, they participate in neural development, cellular homeostasis, and both, 
physiological as well as pathological processes [1]. 
 
Research on autophagy is a constantly increasing field of research in neuroscience, 
since autophagy is activated in neurodegenerative diseases and after acute brain injury, 
but proper functioning of this catabolic pathway is also required for the intracellular 
homeostasis of neuronal cells and thereby brain functions [25]. In the long term, 
autophagy is essential for neuronal function and survival, whereas impaired autophagy 
appears to be a contributing factor in chronic neurodegenerative diseases [26, 27]. There 
are, however, still many fundamental questions about the mechanisms governing 
autophagy in neuropathies. Therefore, one aim of this study was to investigate the 
role of autophagy in neurons under stress, in the model system of glutamate-induced 
oxytosis in neural HT-22 cells. Recently, it was shown that autophagy is activated by 
increased intracellular ROS levels [59]. Therefore, the objectives were to determine the 
effect of oxidative glutamate toxicity on autophagic flux and to investigate if oxytosis 
involves autophagy pathways of cell death. Moreover the neuroprotective effect of 3-
Methyladenine (3-MA), a widely used autophagy inhibitor, was explored in the model 
systems of glutamate-induced oxytosis and excitotoxicity in neural HT-22 cells and 
primary cortical neurons, respectively. 
 
The contribution of apoptosis to neuronal survival through intercellular signaling 
between dying cells and neurons was investigated using conditioned medium of neural 
progenitor cells and HT-22 cells. Stem cells as well as progenitor cells have been 
widely used in model systems of neurodegenerative diseases and acute brain injuries 
where transplantation of these cells into the brain improved neuronal survival and brain 
functions in experimental settings. However, most transplanted cells die after 
transplantation in vivo [148–150], and the exact mechanism of action of stem cell or 
progenitor cell transplantation still remains unknown. To investigate mechanisms of 
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intercellular signaling underlying the protective effects of transplanted stem cells, the 
transplantation conditions were mimicked in vitro by preparation of conditioned 
medium (CM) obtained from dying neuronal progenitor cells or HT-22 cells. This CM 
should contain similar cellular components as released during cell death of the 
progenitor cell transplants, and this CM should therefore also provide neuroprotective 
effects. Thus, the CM of apoptotic cells was applied in model systems of cell death in 
vitro for its potential to mediate neuroprotection. Further, the composition of the 
conditioned medium obtained from the dying cells was analysed for identifying the 
most potent protective components that may be applied as neuroprotectants in vitro and 
in vivo instead of the CM or the cellular transplants. 
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2 Materials and Methods 
2.1 Cell culture 
2.1.1 Cell culture materials 
Sterile cell culture dishes and other materials were obtained from Greiner 
(Frickenhausen, Germany), Sarstedt (Nümbrecht, Germany), Ibidi (Munich, Germany), 
Whatman (Dassel, Germany), B. Braun (Melsungen, Germany), Millipore (Schwalbach, 
Germany). The xCELLigence system and E-plates were provided by Roche, Applied 
Science (Penzberg, Germany). 
 
Table 1. Plastic ware 
Plasticware Company  
T75 flasks Greiner, Frickenhausen, Germany  
T175 flasks Greiner, Frickenhausen, Germany 
6-well plates Greiner, Frickenhausen, Germany 
24-well plates Greiner, Frickenhausen, Germany 
96-well plates Greiner, Frickenhausen, Germany 
Ibidi slides 8-well plates Ibidi, Munich, Germany  
15 ml tubes Sarstedt, Nümbrecht, Germany 
50 ml tubes Sarstedt, Nümbrecht, Germany 
0.5, 1.5, 2 ml tubes Sarstedt, Nümbrecht, Germany  
Cellscraper Sarstedt, Nümbrecht, Germany  
0.22 μm sterile filter Whatman, Dassel, Germany 
5, 10 ml Injekt® B. Braun, Melsungen, Germany 
3, 10, 50 kDa Amicon® Ultra Centrifugal 
Filter Units 
Millipore, Schwalbach, Germany 
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2.1.2 Cell lines 
2.1.2.1 HT-22 cells 
HT-22 cells are immortalized hippocampal neurons from mice. This cell line was 
obtained from Gerald Thiel with kind permission of David Schubert (Salk Institute, San 
Diego, California, USA). HT-22 cells were maintained in Dulbecco’s modified Eagle 
medium (DMEM, Sigma-Aldrich, Taufkirchen, Germany) and cultured in a standard 
humidified incubator (Thermo Scientific, Dreieich, Germany) at 37°C and 5 % CO2. 
DMEM was completed with 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM glutamine (all Sigma-Aldrich). HT-22 cells were plated at 
different densities (table 2) on 6-, 24, 96-well plates (Greiner), E-plates (Roche Applied 
Science), or ibidi slides 8-well plates (Ibidi). Treatment of HT-22 cells started 24 h after 
plating the cells. 
Table 2. HT-22 cells – cell densities 
Cell culture format Cell density (cells/well) 
6-well plate ~ 180,000  
24-well plate ~ 60,000  
96-well plate ~ 8,000  
Ibidi slide 8-well plates ~ 16,000  
E-Plate ~ 10,000  
 
2.1.2.2 Induction of cell death in HT-22 cells with glutamate 
HT-22 cells were treated when cells reached 70-80 % confluency. For induction of cell 
death in HT-22 cells, glutamate was used at a final concentration ranging from of 3 to 7 
mM. For the glutamate stock solution, D,L-glutamic acid monohydrate (Sigma-Aldrich) 
was dissolved in DMEM (Sigma-Aldrich) to a stock concentration of 1 M. The pH was 
adjusted to 7.2 with concentrated sodium hydroxide solution (NaOH). The stock 
solution was stored at -20°C. For the induction of cell death, the stock solution was 
diluted with DMEM to final concentrations directly before the treatment and added to 
the cells.  
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2.1.2.3 Neural progenitor cells 
Neural progenitor cells (NPC) were kindly provided by Prof. Dr. Fred H. Gage (Salk 
Institute, La Jolla, USA) [179] and cultured in a standard humidified incubator at 37°C 
and 5 % CO2. NPC were maintained in Dulbecco’s modified Eagle’s medium/nutrient 
mixture F-12 (1:1) medium (DMEM/ Ham’s F12) (PAA Laboratories GmbH, Cölbe, 
Germany or Sigma-Aldrich). DMEM/ Ham’s F12 was supplemented with 1% N2 100x 
(Invitrogen, Karlsruhe, Germany), 1% penicillin 10,000 U/ml/ streptomycin 10mg/ml 
(Invitrogen), 0.2 % epidermal growth factor (EGF) 10 µg/ml (Invitrogen), 0.2 % basic 
fibroblast growth factor (bFGF) 10 µg/ml (Invitrogen), 1 % L-Alanyl-L-glutamine 200 
mM (Sigma-Aldrich) and 0.1 % heparine 5 mg/ml (Sigma-Aldrich). NPC growth 
medium was freshly prepared and used within 1-2 weeks since stability of the growth 
factors is limited. NPC were plated at different densities (table 3) on 24-, 96-well plates 
(Greiner) or E-plates (Roche Applied Science). Treatment of NPC cells started after 48 
h in culture. 
Table 3. NPC densities 
Cell culture format Cell density (cells/well) 
24-well plate ~220,000 
96-well plate ~ 40,000 
E-Plate ~ 27,000- 40,000 
 
2.1.2.4 Preparation of conditioned medium (CM) via starvation 
Neural progenitor cells and mouse embryonic fibroblasts (MEF) were used for the 
production of conditioned medium. CM was prepared after EGF- and bFGF-deprivation 
or EBSS-treatment. Cells were grown in 75 cm
2 
culture flasks until they reached ~70 % 
confluency or on 96-well plates at a density of 20,000 cells/well. Culture media was 
removed and cells were washed once with PBS and incubated with Earle’s balanced salt 
solution (EBSS) (1x, Sigma-Aldrich) or DMEM/ Ham’s F12 (Sigma-Aldrich), 
supplemented with 1 % N2-supplement (Invitrogen). NPC CM and MEF CM were 
collected 24 h after growth factor deprivation and stored at -80°C. For applications in 
HT-22 cells, conditioned medium was produced with EBSS. PCN were treated with 
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conditioned medium produced with DMEM/ Ham’s F12 supplemented with 1% N2-
supplement (Invitrogen). Before use, CM was centrifuged (1,000 rpm, 10 min) and 
filtered through a 0.22 m membrane filter (Whatman) to remove dead cells and cell 
debris. For heat activation, CM was heated up to 90°C for at least 10 min. CM was used 
with 6 h pretreatment followed by glutamate treatment if not described otherwise. 
 
2.1.2.5 Production of spermidine-conditioned medium (Sp CM) 
HT-22 cells were used for the production of Sp CM. Conditioned medium was prepared 
after treatment with spermidine (1 µM, 10 µM and 25 µM). Cells were grown in 75 cm
2
 
culture flasks until they reached ~70 % confluency. Culture media was removed and 
cells were incubated with DMEM. DMEM was supplemented with 10% fetal calf 
serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine and spermidine 
at different concentrations. Sp CM was collected 24 h after treatment stored at -80°C. 
Before use, CM was centrifuged (1,000 rpm, 10 min) and filtered through a 0.22 m 
membrane filter (Whatman) to remove dead cells and cell debris.  
 
Table 4. Phosphate buffered saline (PBS), pH 7.4 
PBS, pH 7.4  
NaCl 9 g 
Na2HPO4 0.527 g 
KH2PO4 0.144 g 
HCl (0.1 M) q.s. for pH adjustment 
Aqua demin. add to a final volume of 1,000 ml 
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Table 5. Earl’s balanced salt solution (EBSS 1x) containing phenol red 
EBSS 1x, pH 7.4  
EBSS 10x  100 ml 
NaHCO3 2.2 g 
Aqua demin. add to a final volume of 1,000 ml 
HCl (0.1 M) q.s. for pH adjustment 
 
2.1.3 Primary cultures 
2.1.3.1 Primary cortical neurons 
Primary neurons were prepared from cortices of embryonic rats (E 16- 18) (Janvier, Le 
Genest St. Isle, France). Briefly, cortices were removed and neurons were separated by 
mechanical dissociation after mild trypsinisation of the isolated cortical tissue. Isolated 
cortices were incubated in Hank’s balanced salt solution (HBSS, diluted from 10x 
HBSS, Invitrogen) containing 1 mg/ml trypsin (Sigma-Aldrich) for 15 min at 37°C. The 
cortices were then washed with HBSS and mixed with HBSS containing 1 mg/ml 
trypsin inhibitor (Sigma-Aldrich) and the cell suspension was incubated for further 2 
min at room temperature. Afterwards, the cortices were washed two times with HBSS, 
and triturated in MEM+ obtained from Eagle’s minimum essential medium (Invitrogen) 
by addition of 1 mM HEPES (Biomol, Hamburg, Germany), 26 mM NaHCO3, 40 mM 
glucose, 20 mM KCl, 1.2 mM L-glutamine (each Sigma-Aldrich), 1 mM sodium 
pyruvate (Biochrom, Berlin, Germany), 10% (v/v) fetal calf serum (FCS) (Invitrogen) 
and 10 mg/l gentamicin sulfate (Sigma-Aldrich). Cortical cells were plated at a density 
of 7x10
5 
cells/ cm
2 
on polyethylenimine (Sigma-Aldrich) pre-coated 96-well plates 
(Greiner) or 35 mm culture dishes (Greiner). Primary neurons were cultured in 
Neurobasal medium (Invitrogen), supplemented with HEPES 5 mM (Sigma-Aldrich), 
glutamine 1.2 mM (PAA), B27 supplement 2% (v/v) (Invitrogen), and gentamicin 0,1 
mg/ml (Sigma-Aldrich). After 48 h, neurons were treated with cytosine 
arabinofuranosid for another 48 h. All experimental treatments were performed in 6-8 
day-old cultures.  
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2.1.3.2 Mouse embryonic fibroblasts 
Mouse embryonic fibroblasts (MEF) were prepared from C57BL/6mice on gestation 
day 18. Small pieces of embryonic skin were dissected and put into MEF culture media, 
consisting of Dulbecco’s modified Eagle’s medium (DMEM) high glucose (4.5 g/L) 
and 110 mg/l sodium pyruvate (PAA) with FCS 15 % (PAA), penicillin 10.000 U/ml / 
streptomycin 10mg/ml 1 % (Invitrogen), L-Alanyl-L-glutamine 200 mM 2 % (PAA). 
MEF attached and began to divide in 1-3 days. Cells were split in the same procedure as 
HT-22 cells when reaching ~80 % confluency on the flask bottom. Passages 1-3 were 
used for further experiments and plated at a density of 20.000 cells/cm
2
. All cell types 
were incubated at 37°C in a humidified atmosphere containing 5% CO2. 
 
2.2 Chemicals and Reagents 
All chemicals and reagents were obtained from Sigma-Aldrich and Carl Roth 
(Karlsruhe, Germany), if not described otherwise.  
Buffers and solutions were prepared using demineralized, ultrapure water, prepared 
with the SG Ultra Clear UV plus Reinstwassersystem (VWR, Darmstadt, Germany). 
Steam autoclaving (steam autoclave, Systec V-40, Systec GmbH, Wettenberg, 
Germany) was used to further sterilize ultrapure, demineralized water for the use in cell 
culture preparations. All media and solutions that were used for cell culture experiments 
were sterilized by filtration using 0.22 µm filter sets (Sarstedt). 
 
2.2.1 Pharmacological inhibitors or activators 
For inhibition of caspases, the cell-permeable, irreversible, broad-spectrum caspase 
inhibitor Qvd-OPh (Calbiochem, Darmstadt, Germany) was used. The solution 
dissolved in DMSO (10 mM) was used at a final concentration of 20-40 μM.  
Brain-derived neurotrophic factor (BDNF, R&D Systems GmbH, Wiesbaden, 
Germany) was dissolved in DMSO at a stock concentration of 10 μg/ml and stored at -
20°C. For treatment in primary neurons, a final concentration of 10 ng/ml was used.  
For inhibition of phosphoinositide-3-kinase (PI3K) the cell-permeable, reversible 
inhibitor LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, Sigma-
Aldrich) was used. LY294002 was dissolved in DMSO resulting in a 1 mM stock 
solution. For HT-22 cell treatment a final concentration of 10 μM was applied. Cells 
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were pretreated with the inhibitor for 1 h followed by a pretreatment containing CM and 
the inhibitor together. Afterwards, cells were damaged by glutamate.  
3-MA (Sigma-Aldrich), a widely used inhibitor of autophagy, was used at a final 
concentration of 5 mM. The stock solution (100 mM) was stored at -20°C. Before use, 
the stock solution was heated (60°C) until the solution was clear.  
The selective Bid inhibitor BI-6C9 (Sigma-Aldrich) was dissolved in DMSO at a 
concentration of 10 mM. For experiments in HT-22 cells a final concentration of 10 µM 
was used.  
For inhibition of the activation of mitogen-activated protein kinase kinase (MAPKK) 
the specific inhibitor PD 98059 (Sigma-Aldrich) was used. PD 98059 was dissolved in 
DMSO resulting in a 10 mM stock solution. For HT-22 cell treatment a final 
concentration of 50 μM was applied. Cells were pretreated with the inhibitor for 1 h 
followed by a treatment containing 3-MA and the inhibitor together.  
Blebbistatin (Sigma-Aldrich) is a cell permeable, specific inhibitor of non-muscle 
myosin II. The substance was dissolved in DMSO (50 mM). Blebbistatin was used at 
concentrations ranging from 5 µM-100 µM. 
Y-27632 (Sigma-Aldrich) is a highly potent, cell-permeable, selective ROCK (Rho-
associated coiled coil forming protein serine/threonine kinase) inhibitor. Y-27632 was 
dissolved in DMSO (10 mM) and used at final concentrations ranging from 1 µM-50 
µM. 
 
2.3 Cell viability assays 
2.3.1 MTT-assay 
The MTT (3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) (Sigma-
Aldrich) -assay, was used to determine cell viability in NPC, MEF, HT-22 cells and 
primary neurons. The MTT assay is a colorimetric assay for measuring the activity of 
enzymes that reduce MTT to a formazan by either a lysosomal/endosomal compartment 
or mitochondria [180], resulting in a purple color. After indicated time points, when the 
typical rounded formation of cells indicated cell death, the MTT reagent was added to 
the media at final concentrations of 0.25-0.5 mg/ml followed by 1 h incubation at 37°C. 
The reaction was terminated by removing the media from the cells and freezing the 
plate at -80°C for at least 1 h. Absorbance was determined after solving the formazan 
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crystals in dimethyl sulfoxide (DMSO, Sigma-Aldrich) at 570 nm with the FLUOstar 
Optima reader (BMG Labtech, Offenbach, Germany). The background was detected at 
630 nm and substracted accordingly. Cell viability was expressed as absorption level 
relative to controls, which were set to viability values of 100%. 
 
2.3.2 The xCELLigence system 
The xCELLigence system monitors cellular events in real time by measuring electrical 
impedance across interdigitated gold micro-electrodes integrated on the bottom of tissue 
culture E-plates. Usually, cells have a high electrical resistance and, thus, the more cells 
cover the electrodes, the larger are the increases in impedance. Following this, the 
system is able to detect changes in cell number (proliferating cells), altered attachment 
properties (cellular death), and especially the kinetics of these processes. The results are 
depicted as a curve indicating the cell index as a function of time [181]. For using this 
system 8,000 HT-22 cells or 30,000-40,000 NPC per well were seeded into 96-well E-
plates. Prior to seeding the cells, background impedance was determined using 100-200 
μl of cell culture medium or EBSS. Next, cell suspension was added to a total of 100 
μl/well for HT-22 neurons and 200 μl/well for NPC. Treatment of cells was initiated 
when the cell index exceeded a value of about one. Cell index values were recorded 
using RTCA Software 1.2 (Roche Diagnostics). After concluding each experiment, E-
plates were recycled by removing media, washing the plates twice with demineralized 
water and adding standard Trypsin/EDTA (TE) for 15-20 min. Afterwards 1x TE was 
removed, the plates were washed a further 3 times and irradiated with UV light for 30 
min to reassure sterility.  
 
2.3.3 FACS-Annexin V-FITC/ PI Apoptosis-Necrosis measurement 
Annexin V-FITC/ propidiumiodide (PI) staining identifies cells in early apoptosis by 
detecting externalized phosphatidylserine, and PI identifies cells that have lost plasma 
membrane integrity (i.e., necrotic or late apoptotic cells). For annexin V-FITC/ 
propidium iodide-staining, HT-22 cells were cultured in 24-well plates and treated with 
glutamate. Cells were harvested 15 h after the onset of the glutamate, washed and 
resuspended in binding buffer (PromoKine, Heidelberg, Germany). Then 2.5 µl of each 
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propidium iodide and annexin-V-FITC solutions (PromoKine Annexin V-FITC 
Detection Kit, PromoKine) were added respectively, and incubated for 5 min at room 
temperature in the dark. Apoptotic and necrotic cells were detected using a FACScan 
(Guava Easy Cyte, Merck Milipore, Darmstadt, Germany). Annexin-V and 
propidiumiodide fluorescence were excited at a wavelength of 488 nm. Emissions were 
detected at 530±40 nm for annexin-V and at 680±30 nm for propidiumiodide. Data were 
collected from at least 10,000 cells. Measurements are representative of at least three 
independent experiments. 
 
2.3.4 DAPI-Counting 
For quantification of pyknotic nuclei in primary cortical neurons exposed to trophic 
factor withdrawal or glutamate, cells were fixed with PFA 4% after 16-24 h of treatment 
and incubated with the fluorescent DNA binding dye DAPI (4’, 6-diamidino-2-
phenylindole dihydrochloride (DAPI), 1 µg/ml, Sigma-Aldrich). The percentage of 
pyknotic nuclei was quantified from pictures obtained with a fluorescence microscope 
(DMI 6000 B, Leica, Wetzlar, Germany) connected to a CCD camera (DFC 360 FX, 
Leica, Wetzlar, Germany). Neurons with condensed and fragmented nuclei were 
considered apoptotic. About 1000 cells per treatment condition were counted, and 
counts were made in five separate cultures without knowledge of the treatment history. 
 
2.4 Analysis of cellular morphology 
To analyze cellular morphology of HT-22 cells or NPC, light microscopy was 
performed using the Axiovert 100 microscope (Zeiss, Jena, Germany). Pictures were 
taken using the Infinity 2 camera running Infinity Capture Software (Lumenera, Ottawa, 
Canada). 
 
2.5 Visualization and characterization of mitochondria 
For analysis of mitochondrial morphology, cells were stained with MitoTracker Deep 
Red (Invitrogen). HT-22 cells were seeded onto Ibidi slides at least 24 h before the 
treatment (16,000 cells/well). MitoTracker DeepRed was dissolved in DMSO at a final 
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stock concentration of 50 μM and kept protected from light. For cell treatment 
MitoTracker reagent was diluted 1:250 in culture medium (final working concentration 
200 nM) together with DAPI (1 μg/ml) for counterstaining the nuclei. Staining solution 
was added to the cells for 20 min before the treatment. At indicated time points, cells 
were fixed with paraformaldehyde 4 % (PFA, Sigma-Aldrich). Nuclei were 
counterstained with DAPI (1 μg/ml). Evaluation and classification of mitochondrial 
morphology was performed as described before [182]. Mitochondria were counted 
manually and categorized in 3 groups, depending on the degree of fragmentation: 
Category I represented cells with intact tubular network with elongated mitochondria 
that are found in cells under control conditions. Category II and III indicated an 
increasing number of fragmented mitochondria. Mitochondrial fragmentation was 
accompanied by an apoptotic phenotype, showing nuclear condensation and the peri-
nuclear arrangement of the mitochondrial fragments. At least 500 cells per condition 
were counted blind to treatment conditions in at least three independent experiments. 
Images for counting were acquired using a fluorescence microscope (DMI 6000B, 
Leica) equipped with LAS AF software (Leica). Pictures were taken using confocal 
laser scanning microscopy (Leica, TCS SP 5). Emission was measured at 665nm with a 
LP650 filter (Leica). 
 
2.6 ATP-assay 
HT-22 cells were seeded in white 96-well plates (Greiner). Twenty-four h after plating, 
cells were cotreated with glutamate (5 mM) and 3-MA (5 mM). ATP levels were 
detected 14 h after treatment by detection of luminescence using the ViaLight MDA 
Plus-Kit (Lonza, Verviers, Belgium). The kit is based upon the bioluminescent 
measurement of ATP that is present in all metabolically active cells. The 
bioluminescent method utilizes an enzyme, luciferase, which catalyses the formation of 
light from ATP and luciferin according to the following reaction:  
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Cells were treated first with a ‘nucleotide releasing reagent’, afterwards ‘ATP 
monitoring reagent’ was injected into each well. Luminescence was detected with the 
FLUOstar Optima reader (BMG Labtech). The emitted light intensity is linearly related 
to the ATP concentration. The values are given as relative values in % to control. 
 
2.7 Detection of lipid peroxides 
For detection of cellular lipid peroxidation, cells were loaded with 2 mM BODIPY 
581/591 C11 (Invitrogen) in regular medium for 60 min. Fourteen h after glutamate 
treatment, attached cells and supernatants were collected, washed and resuspended in 
PBS. Until the measurement cells were kept on ice. Flow cytometry was performed 
using the Guava Easy Cyte (Merck Milipore) system, including Guava Clean 1.3 
software (Merck Milipore) for data analysis. A 488 nm UV line argon laser was used 
for excitation measurements. BODIPY emission was recorded at 530 nm and 585 nm. 
Data were collected from at least 10,000 cells. Measurements are representative of at 
least three independent experiments. 
 
2.8 Detection of mitochondrial membrane potential 
For detection of changes of MMP (ΔΨm), the MitoPTTM TMRE kit 
(Immunochemistry Technologies, Hamburg, Germany) was used. HT-22 cells were 
incubated for 20 min at 37° C with tetramethylrhodamin ethyl ester (TMRE) after 
glutamate treatment. As a positive control for a complete loss of (ΔΨm), FCCP (50 µM) 
protonophore was applied on intact HT-22 cells. Cells were collected, washed with PBS 
and resuspended in assay buffer. Flow cytometry was performed using the Guava Easy 
Cyte system (Merck Milipore). Emission was measured at 680 nm. Data were collected 
from at least 10,000 cells from at least three independent experiments. 
 
2.9 Measurement of cellular oxygen consumption rate (OCR) 
OCR measurements were performed as previously described with minor modifications 
[183] with the help of Dr. Amalia Dolga. HT-22 cells were seeded in a XF 96-well 
microplate (Seahorse Bioscience, Copenhagen, Denmark) at a density of 10,000 cells/ 
well in 4.5 g/L glucose containing growth medium and incubated at 37°C and 5 % CO2 
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for about 20 h. Before each measurement, growth medium was washed off and replaced 
with 180 ml of assay medium (with 4.5 g/L glucose, 2 mM glutamine, 1 mM pyruvate, 
pH 7.35) and then incubated for 60 min at 37°C. Three baseline measurements were 
recorded before the addition of compounds started. Oligomycin was injected in Port A 
(20 µl) at a final concentration of 3 µM. Oligomycin was used to inhibit ATP synthase 
and to determine the leak respiration. Subsequently, carbonylcyanide-4- 
(trifluoromethoxy) -phenylhydrazone (FCCP) was injected in port B (22.5 µl) at a 
concentration of 0.4 µM to uncouple respiration and to determine mitochondrial 
functional capacity. Respiration was finally inhibited with Rotenone/ Antimycin A (Port 
C, 1 µM). Three measurements were performed after the addition of each compound (4 
min mixing followed by 3 min measuring).  
 
2.10 Knockdown of protein expression by siRNA 
For siRNA transfections, the cationic lipid formulation Lipofectamine RNAiMax 
(Invitrogen) was used. Transfections were performed in 24- or 96-well plates as reverse 
transfections. For each well, 1.2 µl (24-well plate) or 0.24 µl (96-well) Lipofectamine 
RNAiMax were mixed with siRNA and filled up to 100 µl (24-well pate) or 20 µl (96-
well plate) with Optimem I (Invitrogen). The mixture was incubated for 20 min at room 
temperature. Afterwards 500 µl (24-well plate) or 100 µl (96-well plate) of an antibiotic 
free cell suspension (18,000 cells/cm
2
) was added. Treatment of cells started 48 h after 
transfection. Gene silencing was verified by Western Blot analysis. Small interfering 
RNA specific for Beclin-1 was purchased from Sigma-Aldrich, siRNA specific for Atg5 
and siRNA specific for class III PI3K were purchased from Thermo Scientific bio 
(Schwerte, Germany) and siRNA targeting MAP LC3β was purchased from Santa Cruz 
(Heidelberg, Germany). Non targeting siRNA was purchased from Eurofins MWG 
Operon (Ebersberg, Germany). The following target sequences were used: siGenome 
mouse PI3K class III siRNA 5’-AUAGAUAGCUCCCAAAUUA-3’, non-targeting 
siRNA 5’-UAAUGU-AUUG-GAACGCAUA-3’, Beclin-1 siRNA duplex of 5’-
CUGAGAAU-GA-AU-GUCAGAA-3’ and 5’-UU-CUGACAUUCAUUCUCAG-3’, 
Atg5 siRNA 5’CCAAUU-GGU-UUA-CUAU-UUG-3’ and MAP LC3β siRNA (Santa 
Cruz, sc-43391). 
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2.11 Protein analysis 
2.11.1 Buffers for SDS PAGE and Western Blot analysis 
 
The separation gel 12.5 % 
1.5 M Tris HCl solution pH 8.8  2.5 ml 
Acrylamide/bisacrylamide (37, 5:1) 30 % 4.0 ml 
Sodiumdodecylsulfate solution 10 %  0.1 ml 
Ammoniumpersulfate solution 10 % 0.05 ml 
Tetramethylethylenediamine (TEMED)  0.01 ml 
Aqua demin.  ad 10 ml 
 
The stacking gel, 3.5 %  
0.5 M Tris HCl solution pH 6.8 2.5 ml 
Acrylamid/bisacrylamide (37.5 : 1) 30 % 1.2 ml 
Sodiumdodecylsulfate solution 10 % 0.1 ml 
Ammoniumpersulfate solution 10 %   0.05 ml 
TEMED 0.01 ml 
Aqua demin.  ad 10 ml 
  
1 x Electrophoresis buffer  
Tris base 3 g 
Glycine 14.4 g 
Sodiumdodecylsulfate (SDS)   1 g 
Aqua demin.   ad 1000 ml 
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5x Sample buffer Western Blot  
1M Tris-HCl pH 6.8 3.75 ml 
Glycerol 7.5 ml 
D,L-Dithiothreitol (DTT) 1.16 g 
SDS    1.5 g 
β-Mercaptoethanol  5 ml 
Bromophenol blue sodium salt   0.0015 g 
Aqua demin.  ad 15 ml 
  
1x Transfer buffer, pH 8.3  
Tris base 3 g 
Glycine   14.4 g 
Methanol 100ml 
HCl 0.1 M   q.s 
Aqua demin. ad 1000 ml 
       
1x TBS, pH 7.5  
Tris base 2.4 g 
NaCl  29.2 g 
HCl 0.1 M q.s. 
Aqua demin. ad 1000 ml 
  
1x TBST, pH 7.5  
Tween 20 500 µl 
1x TBS ad 1000 ml 
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Stripping buffer, pH 2.2  
Glycine 15 g 
SDS  1 g 
Tween 20 10 ml 
HCl conc. q.s. 
Aqua demin. ad 1,000 ml 
 
1x PBS pH 7.4  
NaCl  8 g 
KCl 0.2g 
Disodiumhydrogenphosphate (Na2HPO4) 1.15g 
Potassiumdihydrogenphosphate 
(KH2PO4) 
0.2 
Aqua demin. ad 1000 ml 
 
1x Blocking buffer  
Skim milk powder 25 g 
1x TBST ad 500 ml 
 
2.11.2 Protein preparation and determination 
For obtaining total cell protein extracts, cells were seeded into 24-well or 6-well cell 
culture plates (Greiner). After indicated time points, cells were washed with PBS, 
detached with a cell scraper and exposed to lysis buffer containing mannitol 0.25 M, tris 
base 0.05 M, EDTA 1 M, EGTA 1 M, DTT 1 mM and triton-X 1 % (all Sigma-
Aldrich). The lysis buffer was supplemented with cOmplete ULTRA Mini, EDTA-free, 
EASYpack, Protease Inhibitor Cocktail (Roche) (1 tablet per 10 ml) and PhosSTOP, 
Phosphatase Inhibitor Cocktail (1 tablet per 10 ml). To remove insoluble membrane 
fragments, extracts were centrifuged at 13,000 g for 15-30 min at 4°C. Extracts were 
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frozen at -80°C until further use. Protein concentration was determined in the 
supernatant using a BCA (bicinchoninic acid) protein kit (Thermo Fisher Scientific, 
Bonn, Germany). The BCA protein assay combines the reduction of Cu
2+
 to Cu
1+
 by 
protein in an alkaline medium with the detection of Cu
1+
 by bicinchoninic acid. The 
amount of Cu
2+
 reduced is proportional to the amount of protein present in the solution. 
The first step is the chelation of copper with protein in an alkaline environment to form 
a light blue complex (Biuret reaction). In the second step, bicinchoninic acid reacts with 
the reduced cuprous cation that was formed in step one, which leads to a formation of a 
purple-colored chelate complex. Responsible for this color reaction of the BCA are the 
macromolecular structures of the protein, the amount of peptides and the four amino 
acids cysteine, cystine, tryptophan and tyrosine. The BCA/copper complex exhibits a 
strong linear absorbance at 562 nm with increasing protein concentrations [184]. A 
standard curve containing 0-200 μg bovine serum albumin (BSA) (Perbio Science, 
Bonn, Germany) per 100 μl PBS 1x was prepared. Then, 200 μl of a 1:50 mixture of 
reagent B: reagent A (Perbio Science) was prepared and transferred to each tube. 
Immediately, 5 µl of standards or samples were added. Next, samples were incubated 
for 30 min at 60 °C, followed by pipetting 100 μl of each sample into a 96-well plate 
(Sarstedt). Absorption at 590 nm was determined using a microplate reader (Fluostar 
OPTIMA, BMG Labtech). Protein amounts of the test samples were calculated from the 
standard curve via linear equation. 
 
2.11.3 Gel electrophoresis and Western Blotting 
Sodiumdodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) has been used 
to separate proteins according to their different molecular mass. Gels were prepared 
using Bio-Rad gel casting stand and casting frames (Bio-Rad, Munich, Germany). Gels 
were prepared using a polyacylamide separation gel with a concentration of 12.5 % and 
a stacking gel with 3.5 %. The specific buffers used for the generation of gels and 
subsequent electrophoresis are provided under 2.11.1. Prior to electrophoresis, samples 
were prepared using 25-40 μg of raw protein extract and adding 5 x SDS sample buffer. 
Samples were heated at 90°C for 10 min and loaded onto the gel after reaching room 
temperature. For comparative evaluation of molecular mass, 5 μl of PageRuler TM Plus 
Prestained Ladder (Fermentas, St. Leon-Rot, Germany) were loaded next to the 
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samples. Electrophoresis was performed initially at 60 V for about 30 min to allow for 
sample collection and increased later to 125 V. After electrophoretic separation, 
proteins were transferred on a polyvinylidene fluoride membrane (PVDF, Bio-Rad) 
according to the recommendations by Bio-Rad at 15 V for about 60-120 min. PVDF 
membranes were first activated in methanol and then incubated for 10 min in 1 x 
transfer buffer before blotting. Meanwhile, Whatman blotting paper and the acrylamide 
gel were incubated for 10 min in transfer buffer. Blotting was carried out by stacking 
one layer of Whatman paper on top of the anodic plate, followed by the PVDF 
membrane, the acrylamide gel as the third, and another final layer of Whatman paper on 
top. Blotting was carried out in a Trans-Blot SD semi-dry transfer cell (Bio-Rad) using 
extra thick Whatman filter paper (Bio-Rad) and 1x transfer buffer. After blotting, the 
PVDF membranes were transferred directly into blocking buffer to avoid unspecific 
binding and incubated for 1 h at room temperature. 
Afterwards blots were incubated with the primary antibodies (diluted in blocking 
buffer) overnight at 4°C. The following primary antibodies were used for this thesis: 
anti LC3B, anti Beclin-1, anti p62, anti Atg5, anti class III PI3K, anti cleaved caspase-3, 
anti PARP, anti Akt, anti phospho-Akt, anti Erk1/2, anti phospho-Erk 1/2, anti AMPKα, 
anti phospho AMPKα (all Cell signaling, Danvers, USA, 1:1000), anti actin (1:100,000, 
MP Biomedicals) anti α-tubulin (1:10,000, Sigma-Aldrich), peroxidase-conjugated anti-
rabbit or anti mouse IgG (Vector Laboratories, Peterborough, UK, 1:2500). Actin or 
Tubulin was used as a loading control. The next day, membranes were washed three 
times with TBST for 5 min and incubated with the appropriate HRP-conjugated 
secondary antibody (diluted in blocking buffer, 1:2500, Vector Laboratories) for 1 h at 
room temperature. After washing 3 times with TBST for 15 min each, membranes were 
incubated with chemiluminescent substrate solution HRP-Juice (PJK GmbH, 
Kleinblittersdorf, Germany). Chemiluminescence signals were recorded using x-ray 
films (Thermo Scientific) or by densitometric analysis using the semi-automated 
Chemidoc-XRS Imaging System (Bio-Rad). Quantification of Western Blots was 
performed by using Quantity One analysis software (Bio-Rad). Western Blots of protein 
extracts of PCN were performed with the help of Dr. Amalia Dolga. 
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2.12 Immunocytochemistry 
After indicated time points, NPC or HT-22 cells (plated in Ibidi 8-well plates) were 
washed once with warm PBS and then incubated with 4 % PFA solution for 30 min to 
fixate the cells, followed by a washing step with cold PBS. For permeabilisation cells 
were treated with 0.4 % Triton-X-100 /PBS for 5 min at room temperature. Again a 
washing step with PBS was performed. Cells were then incubated in blocking solution 
(3 % goat serum in PBS, PAA) for 30 min and then exposed to an anti-LC3B antibody 
(1:150 in blocking solution) overnight at 4° C. Negative control cells were not 
incubated with the anti-LC3B antibody. The next day and after two h remaining at room 
temperature, cells were washed three times with PBS and incubated with a Dylight 
antibody (goat Dylight anti rabbit 488, Vector Laboratories, 1:200) for 1.5 h at room 
temperature. After washing three times with PBS cells were ready for microscopic 
analysis. The specificity of LC3B immunoreactivity was controlled by omission of the 
primary antibody. Nuclei were counterstained with DAPI. Fluorescence images were 
obtained using a DMI6000 B inverted microscope (Leica, Germany) and analysed using 
LAS AF Software (Leica Application Suite, Advanced Fluorescence 2.2.0, Leica 
Microsystems).  
 
2.13 Statistical analysis 
The experiments were each performed at least three times. All data points are given as 
means ± standard deviation (S.D.). Statistical comparisons between groups were 
performed with ANOVA (analysis of variance), followed by Scheffé’s or Duncan’s test 
as indicated. A p value of <0.05 was considered to indicate significant differences of the 
compared mean values. Calculations were performed with Winstat standard statistical 
software package (R. Fitch Software, Bad Krozingen, Germany). 
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3 Results 
3.1 3-Methyladenine mediates neuroprotection independent of autophagy 
inhibition 
Oxidative stress has been proposed as a major underlying mechanism of progressive 
neurodegeneration in chronic neurodegenerative diseases, such as AD or PD. Oxidative 
stress has also been linked to activation of autophagy, a pathway by which cytoplasmic 
components are delivered to the lysosome for degradation. However, the impact of 
autophagy on neural cell viability in paradigms of oxidative stress has not been 
elucidated. 
Therefore, the objectives were to determine the effect of the glutamate challenge on 
autophagic flux and to investigate if glutamate-induced toxicity involved autophagic 
cell death. Moreover the neuroprotective effect of 3-Methyladenine (3-MA), a widely 
used autophagy inhibitor, was explored in model systems of glutamate-induced oxytosis 
and excitotoxicity in neural HT-22 cells and primary cortical neurons, respectively. 
 
3.1.1 Glutamate treatment induces autophagy in HT-22 cells and PCN 
Accumulating evidence demonstrates that glutamate-mediated neuronal death involves 
increased formation of ROS and also pathological activation of autophagic pathways. 
Therefore, the question was addressed, whether there is a link between oxidative stress 
and autophagy in the model system of neuronal oxytosis. To this end, first the 
expression levels of LC3 proteins as a major hallmark of autophagic pathways were 
evaluated. The analysis of LC3 in HT-22 cells treated with glutamate (Glu, 5 mM) and 
chloroquine (CQ, 10 µM), a lysosomal inhibitor [185, 186], showed that glutamate 
increased LC3-I to LC3-II conversion (Fig. 4 A). Further, CQ treatment led to a strong 
accumulation of LC3-II in both, controls and glutamate treated cells. These results were 
further confirmed with immunocytochemistry studies. As shown in Fig. 4 B, the 
formation of punctuated LC3 staining indicated the conversion of LC3 (form I to II) and 
its recruitment into autophagosomes. The punctuated LC3 staining increased in HT-22 
cells exposed to 16 h of glutamate in comparison to control cells. CQ treatment led to a 
stronger increase of punctuated LC3 staining in control and in glutamate treated cells. In 
order to evaluate effects of CQ on cell viability after the glutamate treatment, the MTT 
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assay was performed 16 h after the onset of the treatment. Fig. 5 demonstrated that CQ 
had no effect on cell viability in glutamate-treated cells. Together, these results 
indicated an increase of autophagic flux after glutamate exposure in HT-22 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
In PCN, Western Blot analysis of total LC3 I and LC3-II revealed that glutamate 
treatment (10 µM, 20 µM) enhanced the protein levels of LC3-II in comparison to 
control cells (Fig. 6 A). The calculation of the LC3-II/LC3-I ratio showed a dose- 
dependent increase after glutamate treatment, which further indicated that glutamate-
induced excitotoxicity was also able to induce autophagic activity (Fig. 6 B).  
 
 
Figure 4. Induction of autophagy after 
glutamate treatment. A. After incubation 
with glutamate (5 mM) ± chloroquine (CQ, 
10 µM) for 16 h, cells were analyzed by 
immunoblot for LC3 conversion. Immunoblot 
of actin was used as a loading control. B. 
Immunocytochemistry was performed 16 h 
after glutamate (5 mM) ± CQ (10 µM) 
treatment. The formation of LC3 dots was 
examined by fluorescence microscopy.  
Bar scale 25 µm. 
Figure 5. Chloroquine does not 
affect cell viability after glutamate 
treatment. HT-22 cells were treated 
with glutamate (5 mM) ± CQ (10 
µM). Cell viability was determined 
using MTT assay 16 h after treatment.  
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Figure 6. Excitotoxicity is accompanied by activation of autophagy in primary neurons. A. Western 
Blot analysis of LC3 protein levels 24 h after the onset of glutamate (Glu) exposure in primary cortical 
neurons (PCN). Actin immunoblot was used as a loading control. B. LC3-II/LC3-I ratio calculation 
revealed an increase of autophagic activity in PCN challenged with glutamate (Glu).  
 
 
3.1.2 3-MA protects HT-22 cells against glutamate- induced neurotoxicity 
To further investigate the role of autophagy in the model system of glutamate-induced 
cell death, 3-MA was applied as a widely used inhibitor of autophagy [187]. HT-22 
cells were simultaneously treated with glutamate (5 mM) and 3-MA (5 mM) for 16 h. 
Interestingly, 3-MA did not decrease the conversion of LC3-I to LC3-II, neither in 
controls nor in glutamate-treated cells (Fig. 7). Additional treatment with CQ showed an 
increase of LC3-II after 3-MA and glutamate exposure in comparison to control cells, 
indicating that 3-MA even induced autophagic activity. Levels of total p62 were also 
degraded after 3-MA ± glutamate treatment, which was further confirming the ability of 
3-MA to increase the autophagic flux.  
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Figure 7. 3-MA increases molecular hallmarks of autophagy in HT-22 cells. Immunoblot analysis 
was performed 16 h after simultaneous treatment with 3-MA (5 mM) and glutamate (Glu, 5 mM). LC3-II 
protein levels conversion and p62 levels were analyzed to monitor autophagy. Actin immunoblot was 
used as a loading control. 
 
 
Cell viability measurements performed using MTT assay showed that 3-MA 
significantly reduced glutamate toxicity (Fig. 8 A). Post treatment with 3-MA at 1, 3 
and 6 h after glutamate exposure was also determined using the MTT assay. 3-MA was 
able to protect cells from glutamate-induced cell death when applied even 3 h after the 
induction of oxidative stress (Fig. 8 B).  
 
 
Figure 8. 3-MA significantly improves cell survival following glutamate exposure. A. 3-MA (5 mM) 
was added simultaneously with glutamate (5 mM) and the cell viability was measured after 16 h of 
glutamate exposure using the MTT assay (n=8; ***p<0.001, compared to glutamate treated control, 
ANOVA, Scheffé test). B. Post-treatment with 3-MA in the model system of glutamate toxicity. Bar 
graph shows 3-MA post-treatment of HT-22 cells at 1, 3 and 6 h after glutamate exposure. Protective 
effects of 3-MA post-treatment were assessed after 16 h of glutamate exposure using the MTT assay 
(n=8; ***p<0.001, compared to glutamate treated control, ###p<0.001 compared to glutamate treated 
control, ANOVA, Scheffé test). 
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Furthermore, morphological analysis showed that 3-MA prevented HT-22 cell death 
induced by glutamate (Fig. 9 A). 3-MA also significantly reduced the number of 
Annexin V/ PI- positive cells after the glutamate treatment (Fig. 9 B, C). These findings 
were supported by real time measurements with the xCELLigence system showing that 
3-MA prevented the glutamate-induced decrease of the cell index (Fig. 9 D). Taken 
together, these results demonstrated that 3-MA mediated neuroprotection against 
glutamate-induced oxidative stress and 3-MA exerted this protective effect likely 
independently of autophagy inhibition. 
 
 
Figure 9. Neuroprotective effects of 3-MA against glutamate cytotoxicity. A. 3-MA preserved cellular 
morphology following glutamate (5 mM) treatment. B/C. Representative diagrams of Annexin V-FITC/ 
Propidiumiodide staining/ flow cytometry in 3-MA (5 mM) and glutamate (5 mM) treated cells. 3-MA 
was an effective inhibitor of cell death. The values of the upper right (late apoptosis and necrosis) and the 
lower right quadrant (early apoptosis) were combined and statistically analyzed (n=6; ***p<0.001, 
compared to glutamate treated control, ANOVA, Scheffé test). D. xCELLigence real-time measurement 
of HT-22 cells treated with glutamate (5 mM) and 3-MA (5 mM) showed a neuroprotective effect (n=6). 
Cell viability was monitored for 30h. 
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In PCN, 3-MA was also able to protect against glutamate-induced neurotoxicity, 
suggesting a similar pathway for neuronal survival like in HT-22 neuronal cells (Fig. 
10). 
 
 
 
3.1.3 Selective inhibition of essential autophagy proteins does not protect 
HT-22 cells 
To investigate the involvement of autophagy in glutamate-mediated toxicity, siRNA-
mediated gene silencing of Beclin-1 and Atg5 was applied for inhibition of these two 
key regulators of the autophagic process. Both siRNAs used specifically reduced 
Beclin-1 or Atg5 expression after 48 h as shown by immunoblot analysis (Fig. 11 A, B). 
In order to control that reduction of either Beclin-1 or Atg5 protein levels reduced 
autophagic activity, transfected cells were treated with CQ (10 µM) 48 h after 
transfection. Reduction of total Beclin-1 (Fig. 11 A) and Atg5 (Fig. 11 B) led to the 
reduction of both, LC3-I and LC3-II in comparison to vehicle and scrambled siRNA. 
Treatment with CQ led to a strong accumulation of LC3-II in cells incubated with 
vehicle or scrambled siRNA, whereas no accumulation was documented in cells 
exposed to Beclin-1 or Atg5 siRNA. These results confirmed a reduction in autophagic 
flux and the dependency of Beclin-1 and Atg5 for the autophagic process in HT-22 
cells. Further, the selective knockdown Atg5 did not protect HT-22 cells against 
glutamate induced toxicity as shown by MTT analysis (Fig. 11 C) and impedance 
measurements using the xCELLigence system (Fig. 11 D). Interestingly, Beclin-1 
siRNA treatment led to a transient protection against glutamate toxicity as shown by 
Figure 10. 3-MA mediates 
protection against glutamate 
treatment in PCN. MTT assay 
of PCN was performed 24 h 
after 3-MA and glutamate 
cotreatment (n=6; **p<0.01, 
compared to glutamate treated 
control, ##p<0.01, compared to 
glutamate treated control, 
ANOVA, Scheffé test). 
 
 
## 
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real time impedance measurements (Fig. 11 D). MTT analysis only showed a tendency 
of a protective effect by Beclin-1 siRNA in the model system of glutamate toxicity. 
Further, MTT assay of Atg5 siRNA transfected cells that were simultaneously treated 
with 3-MA and glutamate (Fig. 11 C) demonstrated that the reduction of autophagic 
flux did not affect 3-MA mediated neuroprotection. Notably, Beclin-1 siRNA treatment 
increased the neuroprotective effect of 3-MA in the model system of glutamate toxicity. 
Also the combination of Atg5 and Beclin-1 siRNA (each 40 nM) (data not shown) and 
LC3 siRNA (40 nM) (Fig. 12) were tested in the model system of glutamate toxicity, 
but no significant protection was observed using the MTT assay. Efficient knockdown 
of total LC3 protein by applied siRNA was validated before (personal communication, 
Ganjam and Neitemeier). 
 
 
 
Figure 11. Knockdown of total Beclin-1 or Atg5 protein levels in HT-22 cells. A/B. Beclin-1 and Atg5 
knockdown was verified by immunoblot analysis 48 h after transfection. Beclin-1 and Atg5 expression of 
Beclin-1 and Atg5 siRNA (40 nM) transfected cells were compared to non-transfected control cells and 
cells treated with scrambled siRNA. The amount of LC3 conversion was detected in transfected cells ± 
CQ (10 µM) treatment. Actin immunoblot was used as a loading control. C. Cells were challenged with 
glutamate (Glu, 7 mM) 48 h after siRNA transfection. Cell viability was determined using MTT assay 16 
h after treatment (n=6; ***p<0.001, compared to glutamate, scr siRNA and 3-MA treated cells, ANOVA, 
Scheffé test). D. Cells were challenged with glutamate (Glu, 7 mM) 48 h after siRNA transfection. 
Cellular impedance was determined using the xCELLigence system.  
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Figure 12. LC3 siRNA did not protect HT-22 cells against glutamate toxicity. HT-22 cells were 
transfected with LC3B siRNA (40 nM). 48 h after transfection, cells were treated with glutamate in 
different concentrations. MTT analysis was performed 16 h after the onset of glutamate.  
 
In summary, these results indicated that selective inhibition of the autophagic process is 
not sufficient for persistent protection of HT-22 against oxidative stress. Further, 3-MA 
mediated its neuroprotective effects not through direct inhibition of the autophagic 
process. Most interestingly, Beclin-1 silencing further increased the protective effect of 
3-MA in an additive manner.  
 
In addition, the effects of Beclin-1 and Atg5 siRNA were investigated in the model 
system of serum deprivation. Starvation is the best characterized model system to 
induce autophagy in various cell types, including neurons. HT-22 cells were transfected 
with Beclin-1 or Atg5 siRNA (40 nM). MTT assay of transfected cells deprived of FCS 
for 24 h revealed that selective inhibition of autophagy did not prevent cell death (Fig. 
13 A, B). The results that autophagy inhibition did not rescue the cells in the model 
systems of glutamate toxicity and also serum deprivation confirmed the assumption that 
autophagy itself is not causing cell death. This goes along with the perception of the 
majority of recent publications that autophagy is most likely a pro-survival mechanism, 
and even if dying cells show markers of autophagy this alone does not allow the 
conclusion that autophagy mediates cell death [188]. 
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3.1.4 Selective knockdown of class III PI3K does not protect HT-22 cells 
against glutamate-induced oxidative stress 
3-MA is known to inhibit class III PI3K in various cell types, thereby leading to 
inhibition of autophagy. Accordingly, siRNA against PI3K class III was applied to 
investigate the effect of reduced protein levels of PI3K class III in the model system of 
glutamate toxicity in HT-22 cells. The effects of class III PI3K siRNA and 3-MA were 
compared in the presence or absence of glutamate challenge. Western Blot analysis of 
HT-22 cells transfected with siRNA targeting class III PI3K (40 nM) showed a reduced 
expression of total class III PI3K protein 48 h after transfection (Fig. 14 A). The analysis 
of the MTT cell viability assay revealed that knockdown of class III PI3K did not 
protect HT-22 cells against glutamate toxicity (Fig. 14 B). Further, the protective effect 
of 3-MA against glutamate was not changed in cells that were transfected with class III 
PI3K siRNA. These results indicated that the protective effect of 3-MA is not mediated 
through direct inhibition of class III PI3K. 
 
Figure 13. Knockdown of essential 
autophagy proteins does not 
protect against serum deprivation. 
Cells were deprived of serum 48 h 
after siRNA transfection. MTT assay 
was performed 24 h after serum 
deprivation to determine cell 
viability. A. Beclin-1 siRNA (40 nM) 
did not protect HT-22 cell against 
serum deprivation. B. Atg5 siRNA 
(40 nM) did not protect HT-22 cell 
against serum deprivation. 
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Figure 14. PI3K class III knockdown did not attenuate glutamate toxicity. A. PI3K class III 
knockdown was verified by immunoblot analysis 48 h after transfection. PI3K class III expression of PI3K 
class III siRNA (40 nM) transfected cells was compared to non-transfected control cells and cells treated 
with scrambled siRNA (40 nM). B. MTT analysis demonstrated that class III PI3K siRNA (40 nM) did 
not protect HT-22 cells against glutamate toxicity (Glu, 5 mM). The protective effect of 3-MA was not 
changed in the presence of class III PI3K siRNA (n=8; ***p<0.001, compared to glutamate treated 
control, ANOVA, Scheffé test). 
 
 
3.1.5 Akt-inhibitor LY924002 reduces the protective effect of 3-MA against 
glutamate induced oxidative stress 
The PI3K/Akt and the MAPK/Erk-1/2-pathways are important signaling cascades that 
can mediate growth, differentiation and survival in neurons [189]. In order to evaluate 
the functional role of such potential, first, PI3K/Akt activation in the neuroprotective 
effect of 3-MA was blocked by a specific inhibitor. For inhibition of phosphoinositide-
3-kinase (PI3K) class I and thereby indirect inhibition of Akt, the cell-permeable, 
reversible PI3K-inhibitor LY294002 was applied at a final concentration of 10 μM. 
Cells were pretreated with the inhibitor for 1 h followed by a treatment with glutamate 
(5 mM) and 3-MA (5 mM). Cell viability determined by an MTT assay (Fig. 15 A) and 
impedance measurements with the xCELLigence system (Fig. 15 B) showed that 
LY294002 significantly reduced the protective effect of 3-MA in glutamate-treated HT-
22 cells. This result suggested the functional involvement of the PI3K/Akt survival 
signaling pathway in the observed protective effect of 3-MA against glutamate-induced 
neurotoxicity. To demonstrate that LY294002 did not generally inhibit protective 
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mechanisms, HT-22 cells were simultaneously treated with BI-6C9 (10 µM), a widely 
used inhibitor of Bid. The MTT assay revealed no reduction of the protective effect that 
was obtained with BI-6C9 alone (Fig. 15 A).  
Further, immunoblot analysis of protein extracts from HT-22 cells showed a decrease of 
Akt-phosphorylation in 3-MA treated cells with or without glutamate. The decrease was 
prominent already after 30 min of 3-MA treatment (Fig. 15 C) and stable for at least 16 
h (Fig. 15 D). The levels of total Akt remained unchanged. These findings demonstrated 
that 3-MA negatively modulated the PI3K/Akt signaling pathway.  
 
 
 
Figure 15. Involvement of the PI3K/Akt pathway in 3-MA-mediated neuroprotection. HT-22 cells 
were pre-treated with LY294002 (10 µM), followed by the incubation with either 3-MA (5 mM) or BI-
6C9 (10 µM) and glutamate (Glu, 5 mM). A. Cell viability was determined using MTT assay 16 h after 
the onset of glutamate (n=8,***p< 0.001 compared to glutamate treated control, ###p< 0.001 compared to 
glutamate and 3-MA treated cells, ANOVA, Scheffé’s test). B. The xCELLigence system was used 
additionally to monitor the effect of LY294002 (10 µM) on 3-MA mediated neuroprotection. C/D. 
Immunoblot analysis of HT-22 cells treated with 3-MA (5 mM) and/or glutamate (Glu, 5 mM). Phospho-
Akt (p-Akt) and Akt levels were determined after 0.5 h (C) and 16 h of treatment (D). 
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The PI3K/Akt signaling pathway is one of the main regulators of mTOR and thereby 
linked to regulation of autophagic activity. In addition to Akt, the AMP-activated 
protein kinase (AMPK) signaling pathway is another main regulator of mTOR [190]. 
Immunoblot analysis of HT-22 cells treated with 3-MA (5mM) ± glutamate (5mM) 
demonstrated a transient decrease of AMPK phosphorylation after a treatment of 1.5 h 
(Fig. 17). Together, these findings suggested that 3-MA affects at least two different 
signaling pathways, namely the PI3K/Akt and AMPK signaling pathways, which 
modulate cell growth, differentiation, energy homeostasis and survival in neurons.  
 
3.1.6 Role of the MAPK/Erk-1/2 signaling pathway in 3-MA mediated 
neuroprotection 
In order to investigate the involvement of the MAPK/Erk-1/2 pathway in 3-MA 
mediated neuroprotection, immunoblot analysis of Erk phosphorylation and 
pharmacological studies with the MEK 1 inhibitor PD98059 were performed, 
respectively. Immunoblot analysis of protein extracts from HT-22 cells revealed 
enhanced phosphorylation of MAPK/Erk-1/2 within 30 min after exposure of the cells 
to 3-MA ± glutamate. This enhanced phosphorylation of MAPK/Erk-1/2 appeared to be 
transient. Afterwards the signals representing phospho-MAPK/Erk-1/2 declined to 
control levels. The levels of total MAPK/Erk-1/2 remained unchanged, as was observed 
after incubation of the immunoblots with anti-Erk 1/2 antibodies (Fig. 17). 
In addition, the MAPK/Erk-1/2 signaling pathway was blocked using the specific MEK 
1 inhibitor PD98059 (50 µM). PD98059 binds to the inactive forms of MEK1 and 
prevents activation by upstream activators such as c-Raf [191]. MTT analysis 
demonstrated that pre-incubation for 1h with PD98059 protected HT-22 cells against 
glutamate-induced toxicity (Fig. 16). This result indicated that the MAPK/Erk-1/2 
pathway is not involved in 3-MA-mediated neuroprotection, however a transient 
increase in Erk 1/2 phosphorylation was detected within 30 min after exposure of 3-MA 
± glutamate. 
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Figure 17. Effects of 3-MA on the AMPK and MAPK/Erk-1/2 signaling pathways. Protein extracts 
from HT-22 cells were collected 0.5 h, 1 h, 1.5 h and 2 h after treatment with 3-MA (5 mM) ± glutamate 
(5 mM). Protein levels of pAMPK, AMPK, p-Erk and Erk were determined using immunoblot analysis. 
Tubulin was used as a loading control.  
 
 
 
 
 
 
Figure 16. PD98059 protects HT-
22 cells against glutamate toxicity. 
MTT analysis was used to 
determine the effect of PD98059 
(50 µM) in the model system of 
glutamate (Glu, 5 mM) toxicity 16 h 
after treatment (n=8; ***p<0.001, 
compared to glutamate treated 
control). 
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3.1.7 3-MA treatment preserves mitochondrial integrity 
Next, the effects of glutamate and 3-MA on mitochondrial morphology and function 
were examined. Mitochondria generate most of the cell's supply of ATP. In addition, 
mitochondria are involved in the regulation of other fundamental cellular functions such 
as mitochondrial retrograde signaling, cellular differentiation, cell death, as well as the 
control of the cell cycle and cell growth [192]. Mitochondria have also been implicated 
in several human diseases, including neurodegenerative diseases [193].  
After glutamate treatment, most cells showed significant fragmentation of the 
mitochondria appearing as small round organelles in the damaged cells in contrast to 
long tubular mitochondria observed under control conditions [182, 194]. 3-MA 
preserved mitochondrial morphology despite glutamate exposure, and mitochondria 
remained as a network of long tubular organelles similar to controls (Fig. 18 A). 
Quantification of mitochondrial morphology confirmed these results (Fig. 18 B).  
 
 
Figure 18. 3-MA preserves mitochondrial morphology after glutamate exposure. A. HT-22 cells 
were stained with MitoTracker red 30 min before glutamate (Glu, 5 mM) and 3-MA (5 mM) treatment. 
Fluorescence microscopy was performed 16 h after the treatment. Red color indicated mitochondria. Bar 
scale 25 µm. B Quantification of mitochondrial morphology: Category I (Cat I): fused, Category II (Cat 
II): intermediate, Category III (Cat III): fragmented mitochondria. At least 500 cells were counted per 
condition blinded to treatment conditions. Values are given from three independent experiments 
(###p<0.001 compared to category III glutamate treated control; ***p<0.001 compared to category I 
glutamate treated control). 
 
 
R e s u l t s | 54 
 
 
Further, the formation of lipid peroxides, which are associated with irreversible 
mitochondrial damage and ROS formation, was analyzed. As detected by the 
fluorescent dye BODIPY (4,4-difluoro- 5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-
diaza-s-indacene- 3-undecanoic acid) and fluorescence-activated cell sorting (FACS) 
analysis, glutamate-induced cell death was accompanied by an accumulation of lipid 
peroxides (Fig. 19 A, B). 3-MA treatment significantly reduced the production of lipid 
peroxides compared to controls exposed to glutamate. To assess the functional integrity 
of mitochondria in 3-MA treated cells, we next investigated ATP levels after glutamate 
exposure. Since glutamate treatment results in a rapid decrease in cytoplasmic ATP 
levels, we next evaluated if 3-MA is able to reduce the decrease of cytoplasmic ATP 
levels after glutamate treatment [168, 181]. As shown in Fig. 19 D, luminescence 
measurements demonstrated that 3-MA is able to prevent the loss of ATP cells after 
induction of oxidative stress. 
In addition, we investigated the mitochondrial membrane potential (ΔΨm, MMP) in 
glutamate and 3-MA treated cells using tetramethylrhodamin ethyl ester (TMRE 
staining). The loss of mitochondrial membrane potential is detected by a loss of red 
fluorescence that can be measured by FACS analysis. Carbonyl cyanide m- 
chlorophenylhydrazone (FCCP, 50 µM) that induced a fast and strong mitochondrial 
depolarization was used as a positive control. Glutamate caused a high loss of 
mitochondrial membrane potential as shown by the reduced number of cells with red 
fluorescence. 3-MA significantly reduced the glutamate-induced loss of mitochondrial 
membrane potential (Fig. 19 C).  
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Figure 19. 3-MA preserves mitochondrial function and integrity in HT-22 cells exposed to 
glutamate. Lipid peroxides were measured by Bodipy FACS analysis 14 h following the onset of 3-MA 
and glutamate treatment. A. Bar graphs showed that 3-MA decreased the amount of lipid peroxides after 
glutamate cotreatment, ***p<0.001 compared to glutamate treated controls (5 mM). B. Graphics obtained 
after FACS analysis. Cells in the upper right quadrant represent cells with increased ROS production. C. 
MMP measured by TMRE is significantly decreased by glutamate treatment (Glu, 5 mM, 15 h) compared 
to control. Membrane potential is preserved by 3-MA (5 mM) (***p<0.001 compared to glutamate 
treated control cells). FCCP was used to dissipate mitochondrial membrane potential and served as a 
positive control. Cells were treated with glutamate (5 mM) for 13 h. D. ATP levels from 3-MA treated 
cells (5 mM) were preserved from loss in ATP levels caused after glutamate treatment (n=8;***p<0.001 
compared to control cells). All statistics were obtained using ANOVA, Scheffé test.  
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3.1.8 3-MA preserves mitochondrial maximum respiration loss mediated 
by glutamate 
Further, the mitochondrial oxygen consumption rate (OCR) using the XFe extracellular 
flux analyzer (Seahorse Bioscience) was examined. The rate of OCR is an indicator of 
mitochondrial respiration and related to catabolic pathways generating ATP. The results 
revealed that glutamate treatment significantly decreased basal cellular respiration, 
maximum respiration and the mitochondrial reserve capacity as compared to non-
glutamate exposed cells. 3-MA treatment alone did not affect basal respiration, but 
prevented the decreases of mitochondrial respiration parameters induced by glutamate 
treatment (Fig. 20). These data confirmed that 3-MA prevented mitochondrial damage, 
thereby, rescuing the HT-22 cells from glutamate-induced oxidative stress. 
 
 
 
Figure 20. Mitochondrial oxygen utilization in glutamate treated cells. Oxygraph traces showing 
respiratory activity of HT-22 cells exposed to glutamate (4 mM) with or without 3-MA (5mM) after 16 h 
of treatment. A indicated the additions of oligomycin (OM), B the addition of Carbonylcyanide p-
trifluoromethoxyphenylhydrazone (FCCP) and C the addition of Rotenone and Antimycin A.  
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3.2 Neuroprotection mediated by conditioned medium (CM) of neuronal 
cell lines 
3.2.1 Conditioned medium of neural progenitor cells protects neuronal cells 
against growth factor withdrawal and glutamate-induced neurotoxicity 
 
Beneficial effects of neural progenitor cell (NPC) transplantation have been well 
established in animal models of acute brain damage. However, the cellular and 
molecular mechanisms underlying these protective effects are largely unknown. Since 
only very few NPC cells survive intracerebral transplantation, enhanced neurogenesis 
may only play a minor role for the observed functional and histological protection of 
brain tissue. Therefore, the aim of this part was to explore the neuroprotective potential 
of NPC-conditioned medium (CM) that may be exerted by factors released from these 
cells.  
 
3.2.1.1 Deprivation of growth factors promotes cellular death of NPC 
Local transplantation of NPC into injured brain regions in models of acute brain damage 
revealed significant cellular death of NPC. However, dying NPC mediated protective or 
regenerative effects on neuronal tissues in various models of brain damage. In this study 
the conditions after NPC transplantation in vivo were mimicked in vitro by withdrawal 
of growth factor support in cultured NPC.  
In a first approach to characterize NPC, cellular growth of different cell densities 
(80,000, 100,000, 120,000 cells/cm
2
) was monitored over 48 h (Fig. 21 A). Different 
seeding densities were easily distinguished by different cell indices. For further 
experiments a cell density of 120,000 cells/cm
2
 was used. Next, NPC were deprived of 
both EGF and bFGF (Fig. 21 C). The effects of growth factor deprivation on NPC were 
monitored using the xCELLigence system. Twenty four h after growth factor 
deprivation, the cell index decreased significantly, indicating time-dependent cellular 
death of NPC. The impedance of the control group that was kept in medium containing 
the growth factors increased continuously. After growth factor deprivation the NPC 
shrunk, rounded up and partly detached from the surface of the culture plate (Fig. 21 B). 
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To investigate the cell death mechanisms induced by growth factor deprivation, 
Western blot analysis of caspase-3 and poly [ADP-ribose] polymerase (PARP) was 
performed. Caspase-3 is a key mediator of apoptosis in mammalian cells and 
responsible for the proteolytic cleavage of many key proteins such as the nuclear 
enzyme PARP [195]. PARP is activated in different paradigms of cellular stress, 
mediating either repair mechanisms or cell death, depending on the context and the 
strength of the stress stimulus. Cleavage of PARP serves as a marker of cells 
undergoing caspase-dependent apoptosis [196]. The results showed a time-dependent 
increase in activation of caspase-3 and cleavage of PARP 6 and 12 h after growth factor 
deprivation (Fig. 22).  
 
Figure 21. Cellular growth and effects of growth factor deprivation in NPC. A. Measurement of 
cellular impedance of NPC grown at different densities (80,000 cells/cm
2
, 100,000 cells/cm
2
 and 120,000 
cells/cm
2
), (n = 6). B. Representative pictures of cell morphology of NPC deprived of growth factors (-
GF) (24 h) in comparison to control (Ctrl). C. NPC were plated on an E- plate 96 and deprived of the 
growth factors EGF and bFGF. Cellular impedance was continuously monitored by the xCELLigence 
system (n=6).  
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Figure 22. Cellular growth and effects of growth factor deprivation in NPC. Growth factor 
deprivation induced activation of caspase-3. The immunoblot shows a time-dependent activation of 
caspase-3 and PARP-cleavage 6 h and 12 h after deprivation of EGF and bFGF. The broad caspase 
inhibitor Qvd-OPh (20 µM) prevented activation of caspase-3 and cleavage of PARP.  
 
3.2.1.2 Broad caspase inhibitor Qvd-OPh protects NPC from cellular death 
Further, the broad caspase inhibitor Qvd-OPh was administered to the medium at a final 
concentration of 20 µM. DMSO was used as a standard solvent, the concentration was 
below 0.1% and did not cause any effect on its own. The caspase inhibitor Qvd- OPh 
partly attenuated cell death after growth factor withdrawal in NPC cultures as 
determined with the xCELLigence system (Fig. 23 A). The corresponding MTT assay 
conducted in parallel further supported this observation, thus strengthening the proposed 
correlation between MTT and impedance measurements (Fig. 23 B). Qvd-OPh alone 
did not significantly affect cellular viability in relation to non-treated NPC, as detected 
by the xCELLigence system and the MTT assay. Additionally, Western Blot analysis 
also showed that Qvd-OPh (20µM) was able to prevent caspase-3 activation and the 
cleavage of PARP in the model of growth factor deprivation (Fig. 22). Interestingly, a 
band showing higher molecular weight (~23 kDa) than the large fragment (17, 19 kDa) 
of cleaved caspase-3 was detected. This may reflect the mode of action of the caspase 
inhibitor that irreversibly binds to activated caspases thereby likely stabilizing the 
protein as detected in the current immunoblot analysis [197]. 
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Figure 23. Broad caspase inhibitor Qvd-OPh protects NPC against cell death induced by 
deprivation of growth factors. A. NPC were treated with Qvd-OPh (20 µM). Real time monitoring of 
cellular impedance by the xCELLigence system revealed a protective effect of Qvd-OPh 48 h after 
deprivation of EGF and bFGF (-GF) (n=6). B. MTT-assay confirmed the protective effect of Qvd-OPh 
against growth factor withdrawal (-GF) in NPC (***p<0.001 compared to control after growth factor 
deprivation; n=8, ANOVA, Scheffé test).  
 
3.2.1.3 NPC conditioned medium protects neuronal cells against damage by 
growth factor withdrawal and glutamate toxicity 
The development of a CM from dying NPC reflects the conditions after stem/progenitor 
cell injection. Therefore, the aim was to explore the potential of NPC-conditioned 
medium (NPC CM) to attenuate growth factor withdrawal and glutamate-induced 
neuronal death. In many settings of acute and chronic neurodegeneration, oxidative 
stress and glutamate-induced deregulation of intracellular calcium homeostasis are 
considered as the major triggers of neuronal cell death [174, 175]. Here, NPC CM was 
applied in the model system of glutamate-induced toxicity in order to evaluate the 
potential neuroprotective effects of factors released by NPC. 
In HT-22 cells, millimolar concentrations of glutamate induce NMDA-receptor 
independent cell death through enhanced oxidative stress, mitochondrial damage and 
the release of mitochondrial apoptosis-inducing factor (AIF), a process termed oxytosis 
[167, 182]. In contrast, micromolar concentrations of glutamate induce excitotoxicity 
and calcium-triggered cell death through activation of NMDA receptors in primary 
cortical neurons [173]. HT-22 cells, PCN and NPC cells were pre-treated for 6 h with 
NPC conditioned medium (NPC CM) and then challenged with glutamate for 18 h or 
deprived of growth factors for 24 h. In the experimental setups growth factor 
deprivation and glutamate treatment led to cellular death of about 60-90% (Fig. 24 A- 
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C). NPC CM elicited neuroprotective effects against growth factor deprivation and 
glutamate-toxicity in both HT-22 (Fig. 24 A) and PCN cells (Fig. 24 B) as shown by 
MTT analysis. In NPC, NPC CM protected cells significantly against growth factor 
deprivation (Fig. 24 C). These findings indicated that NPC secrete protective factors 
that attenuate growth factor withdrawal and glutamate-induced neurotoxicity. To check 
whether the neuroprotective effects of CM were specific to NPC, the effects of 
conditioned medium obtained from MEF cultures were also investigated. MEF CM was 
collected 24 h after nutrient deprivation and prepared like regular NPC CM (see chapter 
2.1.2.4). HT-22 cells were pretreated for 6 h and then treated with glutamate for 
additional 18 h. Cell viability was determined using MTT analysis.  
 
 
 
 
R e s u l t s | 62 
 
 
 
Figure 24. Effects of CM in HT-22 cells, primary cortical neurons (PCN) and neural progenitor 
cells (NPC). A. HT-22 cells were pre-treated with CM for 6 h before exposure to glutamate (5 mM). Cell 
viability was determined 18 h after onset of glutamate. NPC CM protected HT-22 cells against growth 
factor withdrawal (EBSS) and glutamate toxicity. MTT assay was used to determine cell viability 
(***p<0.001 compared to EBSS, ###p<0.001 compared to EBSS treated with glutamate, n=8, ANOVA, 
Scheffé test). B. DAPI staining followed by counting revealed a significant protective effect induced by 
NPC CM against growth factor withdrawal (EBSS) and glutamate toxicity (40 µM) in PCN (***p<0.001 
compared to EBSS, ###p<0.001 compared to EBSS treated with glutamate n=8, ANOVA, Scheffé test). 
C. NPC were treated with NPC CM for 24 h. MTT analysis revealed a strong protective effect against 
nutrient starvation (***p<0.001 compared to EBSS, n=6, ANOVA, Scheffé test). 
 
Interestingly, MEF conditioned medium also protected against growth factor 
deprivation and glutamate-induced neurotoxicity (Fig. 25). However, the 
neuroprotective effect of NPC CM was far more pronounced than the effects obtained 
with the MEF CM.  
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Figure 25. MEF CM protects HT-22 cells against trophic factor withdrawal or glutamate toxicity 
not as strong as NPC CM. HT-22 cell viability measurement indicated a protective effect by both NPC 
and MEF CM against growth factor deprivation (EBSS) and glutamate-induced neurotoxicity (5 mM) 
(***p<0.001 NPC CM and MEF CM compared to EBSS; NPC CM and MEF treated with glutamate 
compared to EBSS treated with glutamate, n=8, ANOVA, Scheffé test).  
 
3.2.1.4 Heating abolishes the protective effect of NPC CM 
Additional experiments aimed at further analyzing the factors that were secreted by 
NPC mediating neuroprotective effects in HT-22 cells and PCN. In a first approach, the 
CM was exposed the CM to 95°C for 30 min in order to achieve denaturation of 
proteins. In contrast to the previously applied native NPC CM, heat-exposed NPC CM 
failed to protect HT-22 cells from glutamate-induced toxicity (Fig. 26). Interestingly, 
heat inactivated NPC CM still provided protective effects against growth factor 
deprivation comparable to native NPC CM.  
 
Figure 26. Heating abolishes protective effects of NPC CM. The NPC CM was incubated at 95°C for 
30 min to generate heat inactivated CM (NPC CM HI) for treatment in HT-22 cells. MTT analysis 
demonstrated a protective effect against glutamate-induced toxicity mediated by NPC CM, but not by 
heat inactivated NPC CM (***p<0.001 compared to EBSS treated with glutamate; n=8, ANOVA, Scheffé 
test). 
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3.2.1.5 Apoptotic bodies have a minor role in the mediation of neuroprotection of 
CM 
Apoptotic bodies have been proposed to enhance the differentiation of human 
endothelial progenitor cells in vitro [198]. Therefore Eva Öxler investigated CM for 
apoptotic bodies to mediate neuroprotection. However, apoptotic bodies isolated from 
NPC did not protect against glutamate-induced cell death whereas the supernatant still 
protected HT-22 cells from apoptosis [199].  
To exclude the possibility that the process to isolate apoptotic bodies was insufficient, 
the involvement of apoptotic bodies in NPC CM-mediated neuroprotection was further 
investigated using a pharmacological approach. NPC were treated with Blebbistatin (50 
µM) or Y-27632 (10 µM) in EBSS. The medium was collected after 24 h and prepared 
for further investigations. Blebbistatin is a selective inhibitor of non-muscle myosin II, 
Y-27632 is a highly potent, cell-permeable, selective ROCK (Rho-associated coiled coil 
forming protein serine/threonine kinase) inhibitor. Both substances inhibit the formation 
of membrane blebs [200]. HT-22 cells were pretreated with Blebbistatin CM (Blebbi 
CM) or Y-27632 CM for 6 h and then challenged with glutamate for 18 h. MTT 
analysis showed that also Blebbistatin CM (Fig. 27 A) or Y-27632 CM (Fig. 27 B) 
protected HT-22 cells against glutamate- induced cell death. It is interesting to note that 
the protective effect of Blebbi CM was less potent than the protective effect that was 
mediated by regular NPC CM, indicating that apoptotic bodies do partly participate in 
NPC CM mediated neuroprotection.  
 
Figure 27. NPC CM prepared with Blebbistatin or Y-27632 mediates neuroprotection. A,B. HT-22 
cells were pretreated with Blebbi CM (A) or Y27632 CM (B) for 6 h and then challenged with glutamate 
for 18 h. MTT assay was used to determine cell viability (n=8, *** p<0.001 compared to glutamate-
treated EBSS, ###p<0.001 compared to glutamate-treated EBSS, ANOVA, Scheffé Test).  
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3.2.1.6 Activation of PI3-K/Akt and MAPK/Erk-1/2 in neurons is involved in 
neuroprotection by preconditioned medium 
To gain further insights into neuroprotective signaling triggered by NPC CM, it was 
next investigated whether this effect was associated with enhanced phosphorylation of 
proteins that were previously established to mediate trophic factor signaling. The 
PI3K/Akt and the MAPK/Erk-1/2 pathways are the most prominent survival signaling 
cascades that can be stimulated in neurons by a wide variety of cytokines or growth 
factors [189, 201]. Rat primary cortical neurons were treated with NPC CM for several 
time points ranging from 10 to 120 min. Western blot analysis was performed to detect 
the rate of phosphorylation of growth factor activated survival signaling proteins, such 
as Akt/PKB and Erk 1/2 after treatment with NPC CM. The results were compared with 
the phosphorylation rate of Akt/PKB and Erk 1/2 after treatment with BDNF (10 
ng/ml). Immunoblot analysis showed an enhanced phosphorylation of Akt/PKB and Erk 
1/2, which was very pronounced after 10 min and remained significantly elevated up to 
120 min after incubation (Fig. 28 A). Quantification of Western blots confirmed these 
results (Fig. 28 B, C). The effects of NPC CM enhancing Akt/PKB and Erk 1/2 
phosphorylation were similar to effects by BDNF. Quantification of immunoblots 
verified a significant increase in Akt and Erk1/2 phosphorylation from 10 to 120 min in 
comparison to control. These findings suggested that the components of NPC CM that 
mediate neuroprotection in vitro or improved neural regeneration in vivo act very 
similar to neurotrophic signaling pathways that were previously shown to provide 
neuroprotection [202]. 
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Figure 28. NPC CM and BDNF activate cell survival-related kinases. A. PCN were treated with NPC 
PCM for several time points ranging from 10 to 120 min. Western blot analysis showed enhanced 
phosphorylation of Akt/PKB and Erk 1/2, similar to the effects after exposure to BDNF. B/C. 
Quantification of Western blot analysis (*p<0.05 compared to control (Ctrl), n=3, ANOVA, Duncan test). 
 
3.2.1.7 Inhibition of autophagy does not protect NPC against EBSS-induced 
starvation 
Autophagic activity is induced by nutrient starvation and is crucial for cell adaption and 
survival under extreme conditions [12]. Therefore it was next addressed, whether the 
process of autophagy contributed to the protective effect of NPC CM in the model 
system of glutamate-induced cell death. Starvation is the best characterized inducer of 
autophagy [58]. Hence, immunocytochemistry and Western Blot analysis were 
performed to investigate if starvation also induces autophagy in NPC. The cells were 
treated with EBSS for 18 h to induce starvation followed by apoptotic cell death. 
Western Blot analysis was performed to investigate protein expression of LC3 after 18 h 
of EBSS treatment. LC3 is an essential protein for the formation of autophagosomes 
and exists in two forms in the cell. Once, autophagy is activated, LC3-I gets lipidated to 
LC3-II and is incorporated into the autophagosome membrane. In cells exposed to 
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serum deprivation both LC3-I and LC3-II were increased in comparison to control cells, 
indicating induction of autophagy after starvation (Fig. 28 A). 3-MA, a widely used 
inhibitor of autophagy, was able to slightly reduce the amount of LC3-II that occurred 
after EBSS treatment (Fig. 29 A), indicating an inhibitory effect on autophagy. Pictures 
obtained with a fluorescence microscope clearly revealed an increase of green dot 
agglomerations and an increase in fluorescence intensity in EBSS-treated NPC in 
comparison to control cells (Fig. 29 B). The increase of green dot agglomerates 
represents increased formation of autophagosomes [19, 46], indicating activation of 
autophagy. 
 
 
 
 
 
 
Figure 29. EBSS-induced 
autophagy in NPC. A. Western Blot 
analysis of NPC incubated with EBSS 
and 3-MA (5 mM). Protein 
expression of LC3-I and II was 
determined 18 h after the treatment. 
B. NPC were starved with EBSS for 
18 h and afterwards incubated with an 
LC3 antibody (1:150). Dylight goat 
488 anti rabbit was used as a second 
antibody. Fluorescence microscopy 
was performed using an L5 filter. Bar 
scale 50 µM. 
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Next, NPC were pretreated for 2 h or cotreated with 3-MA (5 mM) respectively and 
then challenged with EBSS for 18 h. MTT analysis demonstrated that 3-MA was not 
able to protect NPC against starvation-induced cell death, neither in the pretreated nor 
the cotreated cells (Fig. 30 A).  
 
Figure 30. Effects of 3-MA and NPC CM prepared with 3-MA. A. MTT analysis of pretreatment (2 h) 
or cotreatment with 3-MA (5 mM) of NPC in the model system of EBSS-induced starvation (18 h). B. 
MTT analysis of NPC CM prepared 3-MA compared to regular NPC CM in the model system of 
glutamate-induced toxicity in HT-22 cells (n=8,***p< 0.001 compared to glutamate treated EBSS, 
ANOVA, Scheffé test). 
 
3.2.1.8 NPC conditioned medium prepared with 3-MA protects HT-22 cells 
against glutamate-induced oxidative stress 
Further, the medium of NPC treated with 3-MA and deprived of nutrients was collected 
after 24 h and prepared like regular NPC CM (see chapter 2.1.2.4). Then, NPC CM + 3-
MA was tested and compared with regular NPC CM in the model system of glutamate-
induced oxidative stress in HT-22 cells. MTT cell viability assay showed that NPC CM 
+ 3-MA was as protective as regular NPC CM (Fig. 30 B) against glutamate (5 mM) 
toxicity, even though a slight inhibitory effect on autophagy was detected by Western 
Blot in the cells exposed to EBSS (Fig. 29 A). Therefore it is concluded that autophagy 
induction by trophic factor withdrawal or serum deprivation has no impact on the 
protective effect of NPC CM in the model system of glutamate-induced oxidative stress. 
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3.2.2 Spermidine conditioned medium of HT-22 cells in the model system of 
glutamate-induced oxidative stress 
Spermidine, a polyamine, found in all living organisms, is closely related to cellular 
growth. Recently, spermidine has been shown to increase the lifespan of yeast, 
nematodes, and flies in an autophagy-dependent fashion [203]. Spermidine was used to 
induce autophagy selectively in HT-22 cells. The aim was to investigate, if the 
preparation of spermidine conditioned medium (Sp CM) mediates neuroprotective 
effects that are dependent on autophagy activation.  
 
3.2.2.1 Spermidine induces autophagy in HT-22 cells 
First, the autophagic marker LC3 was analysed by immunoblot analysis and 
immunocytochemistry in spermidine treated cells. For this purpose, HT-22 cells were 
exposed to spermidine (Sp, 1 µM and 20 µM) and chloroquine (CQ, 10 µM) 
simultaneously. Ten h after the onset of spermidine and CQ, HT-22 cells were harvested 
and prepared for immunoblot analysis. As shown in Fig. 31 A, spermidine and CQ 
exposure increased LC3-II accumulation after comparison to control cells. This result 
was further confirmed with immunocytochemistry studies. As shown in Fig. 31 B, the 
punctuated LC3 staining increased in HT-22 cells exposed to 16 h of spermidine in 
comparison to control cells. To analyse effects of chloroquine on cell viability after 
spermidine treatment, MTT assay was performed 16 h after the treatment. Fig. 31 C 
showed that CQ had no effect on cell viability in glutamate treated cells. Altogether, 
these results indicated an increase in autophagic flux after spermidine exposure in HT-
22 cells. 
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Figure 31. Induction of autophagy after spermidine treatment. A. Spermidine treatment induced 
autophagy in HT-22 cells. After incubation with spermidine (1 µM and 20 µM) with or without 
chloroquine (10 µM) for 16 h, cells were analyzed by immunoblot for LC3 conversion. Immunoblot of 
actin was used as a loading control. B. Formation of autophagosomes was increased after spermidine 
treatment. Immunocytochemistry was performed 16 h after spermidine (20 µM) treatment. The formation 
of LC3 dots inside of the cells, representing the recruitment of activated LC3 into autophagosomes, was 
examined by fluorescence microscopy. Bar scale 50 µm. C. Chloroquine treatment (10 µM) had no effect 
on cell viability after spermidine (20 µM) treatment. MTT assay was performed 16 h after the onset of 
spermidine.  
 
3.2.2.2 3-MA protects HT-22 cells against spermidine-induced toxicity 
Next, HT-22 cells were treated with spermidine at different concentrations ranging from 
10 µM to 100 µM for 24 h. MTT assay revealed a dose dependent decrease of cell 
viability in HT-22 cells after the treatment of spermidine (Fig. 32 A). To exclude that 
spermidine toxicity in HT-22 cells is due to an increase of the pH of the medium after 
spermidine treatment, measurements of the pH were performed using the S20-
SevenEasy™ pH meter (Mettler-Toledo GmbH, Giessen, Germany). Spermidine 
slightly increased the pH (control medium: 7.48, spermidine 100µM: 7.58 ), however 
this effect was not strong enough to induce cell death by a pH shift. Cellular death after 
the treatment with spermidine (50 µM) could be prevented with 3-MA treatment (5 
mM). In contrast, the broad caspase inhibitor Qvd- OPh (40 µM) or the Bid inhibitor 
R e s u l t s | 71 
 
 
BI-6C9 (10 µM) were not able to protect against neurotoxic effects of spermidine (Fig. 
32 B). Real time impedance measurements using the xCELLigence system confirmed 
the neuroprotective effect of 3-MA (Fig. 32 C). Light microscopic analysis of cellular 
morphology of HT-22 cells after spermidine challenge and simultaneous 3-MA 
treatment completed the investigation of cell viability and verified the results from 
previous experiments (Fig. 32 D). These results further indicated that autophagy might 
be involved in the cell death mechanism of spermidine. Since 3-MA is not a selective 
inhibitor of autophagy, a gene silencing approach targeting regulator proteins of 
autophagy was obligatory to confirm involvement of autophagy in spermidine-induced 
cell death.  
 
Figure 32. Neuroprotective effect of 3-MA against spermidine cytotoxicity. A. Dose dependent 
toxicity of spermidine after 18 h of treatment in HT-22 cells. Cell viability was determined using the 
MTT assay (n=8). B. 3-MA significantly prevented cell death following spermidine (50 µM) exposure. 3-
MA (5 mM), Qvd-OPh (40 µM) and BI-6C9 (10µM) were added simultaneously with spermidine (50 
µM) and the cell viability was measured after 18 h of glutamate exposure using MTT assay (n=8; 
***p<0.001, compared to glutamate treated control, ANOVA, Scheffé test). C. xCELLigence real-time 
measurement of HT-22 cells treated with spermidine (50 µM) and 3-MA (5 mM) confirmed a 
neuroprotective effect (n=6). D. 3-MA preserved cellular morphologies following glutamate treatment.  
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3.2.2.3 HT-22 cells transfected with Beclin-1 siRNA and Atg5 siRNA in the model 
of spermidine toxicity 
To inhibit the autophagic process selectively, siRNA targeting Beclin-1 and Atg5 was 
applied. The knockdown of total Beclin-1 and Atg5 in HT-22 cells was established 
previously (see chapter 3.1.3). For cell viability experiments, HT-22 cells were 
transfected with Beclin-1 or Atg5 siRNA (each 40 nM) in 96 well plates and then 
challenged with spermidine (25 µM) 48 h after transfection. Cell viability was 
quantified using the MTT assay 18 h after spermidine treatment. The selective 
knockdown of either Beclin-1 or Atg5 did not protect HT-22cells against spermidine-
induced neurotoxicity (Fig. 33 A, B). These results indicated that autophagy is likely 
not involved in spermidine-induced neurotoxicity, however 3-MA mediated 
neuroprotection.  
 
Figure 33. Beclin-1 or Atg5 knockdown did not prevent cell death after spermidine treatment. A. 
Beclin siRNA (40 nM) did not protect HT-22 cell against spermidine toxicity (25 µM). Cells were 
challenged with spermidine (25 µM) 48 h after siRNA transfection. Cell viability was determined using 
the MTT assay. B. Atg5 siRNA (40 nM) also did not protect HT-22 cell against spermidine toxicity (50 
µM). Cells were challenged with glutamate 48 h after siRNA transfection. Cell viability was again 
determined using the MTT assay.  
 
The mode of action of spermidine in the execution of cell death has to be further 
elucidated. Recent findings demonstrated that simultaneous treatment of glutamate (5 
mM) and spermidine (25 µM) strongly increased neurotoxicity in HT-22 cells in 
comparison to single applications (Fig. 34), showing synergistic effects of both 
neurotoxic substances. This indicated two distinct mechanisms leading to HT-22 cell 
death. Spermidine-induced cell death is clearly neither dependent on caspases nor on 
autophagy (Fig 32 B, Fig 33 A, B). 
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Figure 34. Simultaneous treatment of glutamate and spermidine. xCELLigence real-time 
measurement of HT-22 cells treated with spermidine (50 µM) and glutamate (5 mM) simultaneously 
showed stronger neurotoxicity compared to single application of each substance (n=6). 
 
Because of recent findings showing that spermidine improved both survival and 
locomotor activity of the fruit fly Drosophila melanogaster upon exposure to paraquat 
[204], nontoxic concentrations of spermidine (1 µM, 10 µM) were used in the model 
system of glutamate toxicity in HT-22 cells.  
In the model system of glutamate toxicity, spermidine did not exert neuroprotective 
effects (Fig. 35 A). This experiment was followed by the preparation of Sp CM from 
HT-22 cells (see chapter 2.1.2.5). With the preparation of Sp CM, the aim was to 
investigate, if the activation of autophagy via spermidine may lead to the release of 
neuroprotective substances, like it is described for NPC CM, thereby contributing to 
protection of HT-22 against glutamate toxicity. Spermidine CM prepared with low 
concentrations of spermidine did not mediate protection (Fig. 35 B), indicating that sole 
activation of autophagy to release protective substances out of cells into the medium is 
not sufficient to generate a neuroprotective CM. 
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Figure 35. Low concentrations of spermidine are not neuroprotective. A. HT-22 cells were cotreated 
with spermidine (Sp, 1 µM, 10 µM) and glutamate (Glu, 7 mM). MTT analysis was performed 16 h after 
the treatment. B. Spermidine CM (Sp CM) was prepared with low concentrations of spermidine. HT-22 
cells were pretreated 6 h with Sp CM and then challenged with glutamate (Glu, 5 mM). Cell viability was 
determined using the MTT assay 16 h after the onset of glutamate.  
 
3.2.2.4 Spermidine CM from HT-22 cells is not as potent as NPC CM 
Results obtained from NPC CM experiments revealed that caspase-dependent, apoptotic 
cell death of NPC was necessary to obtain neuroprotective NPC CM (see chapter 
3.2.1.3). Therefore, Sp CM was prepared incubating HT-22 cells with a toxic 
concentration of spermidine (25 µM) in regular HT-22 growth medium. Conditioned 
medium was collected after 24 h, centrifuged, filtered and stored at -80°C until further 
use. The Sp CM was applied in the model systems of glutamate-induced cell death and 
spermidine-induced cell death. HT-22 cells were pre-treated with CM for 6 h before 
exposure to glutamate (5 mM) or spermidine (50 µM). Cell viability was determined 18 
h after the onset of each treatment using the MTT assay. Sp CM protected HT-22 cells 
against spermidine toxicity (Sp 25 µM) but not against glutamate-induced toxicity (Fig. 
36 A) or additional spermidine treatment (Fig. 36 B). In conclusion, Sp CM prepared 
from dying cells showed only moderate protective effects, but it was at least more 
potent than Sp CM obtained from HT-22 cells that were treated with nontoxic 
concentrations of spermidine. This finding confirmed that cell death was essential in 
order to produce substantial amounts of protective factors that enhance neuronal 
resilience. The content of protective substances in Sp CM, however, is likely very low, 
which would increase the difficulty of further analysis. 
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Figure 36. Effects of Sp CM in HT-22 cells. Cells were pre-treated with CM for 6 h before exposure to 
glutamate or spermidine. Cell viability was determined 18 h after the onset of each treatment. A. Sp CM 
protected HT-22 cells against spermidine toxicity (Sp, 25 µM) but not against glutamate-induced toxicity 
(5 mM). MTT assay was used to determine cell viability (**p<0.01 compared to spermidine control (Sp), 
n=8, ANOVA, Scheffé test). B. Sp CM protected HT-22 cells against spermidine toxicity (Sp, 25 µM) but 
not against additional spermidine treatment (50 µM). MTT assay was used to determine cell viability 
(***p<0.001 compared to spermidine control (Sp), n=8, ANOVA, Scheffé test) 
 
D i s c u s s i o n | 76 
 
 
4 Discussion 
4.1 3-MA mediates neuroprotection independently of autophagy inhibition 
The aim of the first part of this study was to analyze the role of autophagy in glutamate-
induced neuronal cell death. The involvement of autophagy was characterized in 
immortalized mouse hippocampal HT-22 neurons. Glutamate clearly enhanced 
autophagy markers and induced cell death in HT-22 cells and PCN. Cell death was 
prevented by 3-MA, a widely used inhibitor of autophagy. Interestingly, 3-MA itself 
induced autophagy in HT-22 cells. A gene silencing approach targeting key regulators 
of autophagy reduced the autophagic flux, but failed to prevent cell death persistently. 
Further, the aim was to elucidate the exact mechanism of 3-MA mediated protection in 
the model system of glutamate neurotoxicity. 3-MA prevented the glutamate-induced 
ROS formation, the loss of ATP, and preserved the mitochondrial membrane potential 
as well as mitochondrial morphology.  
The activation of the PI3K/Akt pathway and the MAPK/Erk-1/2 pathway were excluded 
to play a role in 3-MA mediated neuroprotection. In conclusion, these data suggest that 
glutamate toxicity is associated with increased markers of autophagy. However, specific 
gene silencing of key regulators of autophagy did not provide protective effects, 
suggesting that the increased autophagic flux was dispensable for cell death induced by 
glutamate. Further the findings clearly demonstrate that protective effects by 3-MA 
occur independently of autophagy inhibition, although the compound is widely used as 
an inhibitor of autophagy. 
 
4.1.1 Glutamate induces autophagy in HT-22 cells 
HT-22 cells do not express ionotropic glutamate receptors such as NMDA receptors or 
AMPA/Kainate receptors. Therefore, glutamate cannot induce rapid calcium influx and 
excitotoxicity in HT-22 cells but mediates cellular death by inhibition of cystine import 
and subsequent GSH depletion. GSH is an important antioxidative system that also 
regulates the activity of GPx4 and thus indirectly the activity of 12/15 lipoxygenases 
(12/15-LOX) [164–166]. Activation of 12/15-LOX leads to excessive accumulation of 
ROS and cellular death [166]. The present study further revealed that glutamate-induced 
oxidative stress also activated autophagy in HT-22 cells (Fig. 4). In recent publications, 
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ROS were found to regulate autophagy. For example, starvation was found to stimulate 
ROS formation. These oxidative conditions were essential for the modulation of a core 
protein of the autophagic machinery, thereby leading to autophagy activation [59]. Also 
both, exogenously added hydrogen peroxide (H2O2) and endogenous superoxide (O2
•−
) 
produced in the mitochondria have been previously shown to upregulate the formation 
of autophagosomes [205, 206]. 
Markers for autophagy induction including LC3 conversion, suppression of the mTOR 
pathway, and GFP-LC3 dot formation were enhanced by glutamate treatment in HT-22 
cells [207]. Activation of autophagy markers like Beclin-1 and LC3 were also found by 
Kumari et al. after glutamate treatment [208]. Contrary results were reported by Kubota 
et al., who demonstrated that glutamate did not stimulate autophagy in HT-22 cells 
[209]. Since LC3-II itself is degraded by autophagy, LC3 immunoblotting is sometimes 
interpreted inappropriately. Increased levels of LC3-II do not necessarily indicate 
enhanced autophagic flux by glutamate, but may also reflect reduction in 
autophagosome turnover or the inability of turnover to keep pace with increased 
autophagosome formation [45]. Therefore, CQ was applied to investigate whether in the 
present model system glutamate increased autophagic flux. The antimalarial drug CQ is 
a weak base accumulating in acidic organelles like lysosomes. The compound elevates 
lysosomal pH and thereby inhibits autophagy at the step of lysosomal degradation of its 
substrates [185, 186]. The strong accumulation of LC3-II in Western blot and the strong 
increase in dot formation detected by immunocytochemistry after simultaneous 
treatment with glutamate and CQ indicated and increase in autophagic flux by 
glutamate (Fig. 4). The accumulation of LC3-II in control cells treated with CQ 
suggested a high basal level of autophagy in the HT-22 cell line, indicating important 
physiological functions for autophagy in the maintenance of HT-22 cells under standard 
culturing conditions.  
 
4.1.2 Glutamate does not induce autophagic cell death 
The widely used inhibitor of autophagy, 3-MA, suppresses the activity of Vps34, a class 
III phosphoinositide-3-kinase (PI3K) that interacts with Beclin-1 in vesicle nucleation 
during autophagy induction [12, 210]. Inhibition of autophagy by 3-MA was 
demonstrated in many previous studies. For example, 3-MA reduced autophagy in HT-
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22 cells in the model system of serum deprivation [211]. There, addition of 3-MA led to 
a potentiation of cell death induced by serum deprivation in the HT-22 cells. Further, 3-
MA was reported to promote neuroprotection against glutamate in HT-22 cells [207, 
209], which is in line with the present results (Fig. 8). Recent studies involving striatal 
injections of kainate [212] or quinolate [213] showed neuroprotection by 3-MA. Similar 
protection has been obtained in with 3-MA in various models of focal cerebral ischemia 
[214–216].  
Interestingly, 3-MA was also found to promote autophagic flux when MEFs or LC929 
cells were treated under nutrient rich conditions [217], indicating a dual role of 3-MA 
regulating the autophagic process. The results from the present study also suggested an 
increase of autophagic flux after 3-MA treatment (Fig. 7), suggesting that 3-MA is not a 
specific inhibitor of autophagy and that 3-MA did not mediate neuroprotection against 
glutamate toxicity specifically through autophagy inhibition in HT-22 cells. Activation 
of autophagy through 3-MA treatment is possible through inhibition of class I PI3K 
(Fig. 14) and its downstream target mTOR [68, 69]. 
In a selective approach to inhibit autophagy, the knockdown of total Beclin-1, Atg5 or 
LC3 protein reduced autophagic activity, but these approaches were not able to protect 
HT-22 cells against glutamate-induced oxidative stress (Fig. 11). This result strongly 
suggested that glutamate-induced oxytosis did not require autophagic cell death, despite 
the detected increase in autophagic activity after the glutamate treatment. Hence, the 
increase in autophagic activity may be associated with oxytosis, but is not a major cause 
of this form of oxidative cell death.  
Further, additional treatment with 3-MA in Atg5 or Atg5/Beclin-1 siRNA transfected 
cells did not affect neuroprotection mediated by 3-MA (Fig. 11). Interestingly, Beclin-1 
siRNA treatment increased 3-MA mediated neuroprotection against glutamate toxicity. 
The finding that Beclin-1 and not Atg5 downregulation increased 3-MA mediated 
neuroprotection suggested different functions of these proteins in autophagy-dependent 
or autophagy-independent processes [218]. Taken together, these results indicated that 
inhibition of autophagy did not primarily mediate neuroprotection by 3-MA against 
glutamate toxicity.  
After serum deprivation (SD) in HT-22 cells, 3-MA was not able to mediate 
neuroprotection. Unexpectedly, 3-MA even provided a potentiation of cell death 
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induced by serum deprivation [211], which is in line with our results (data not shown). 
In a gene silencing approach to inhibit autophagy in the model system of starvation, no 
protection was achieved (Fig. 13), which emphasizes that the autophagic process is 
rather pro-survival than detrimental to HT-22 cells. Thus, classic induction of 
autophagy via starvation or glutamate treatment did not induce autophagic cell death. 
All cases of cell death that exhibit markers of autophagy such as the lipidation of LC3, 
but cannot be blocked by autophagy inhibition, should not be classified as autophagic 
cell death [92]. The massive accumulation of autophagolysosomes after serum 
deprivation [211] or glutamate treatment (Fig. 4) rather indicated the ultimate attempt to 
survive by adapting to stress and not to execute cell death. Moreover, the role of 
autophagy as a protective mechanism in several types of neurodegenerative conditions 
is well recognized, where it functions to remove ubiquitin aggregates, preventing 
neuronal degeneration. Consistent with this, loss of function of Atg5 and Atg7 causes 
neuronal loss and neurodegeneration [26, 27, 29]. Kuma et al. showed in 2004 [219], 
that mice lacking an autophagy related gene (Atg5) are not able to survive longer than 
12 h after birth because of nutrient shortage. They concluded that nutrient supply by 
autophagy was essential for survival.  
 
4.1.3 Class III PI3K is not affected through 3-MA in HT-22 cells 
It has been established that 3-MA acts via interference with class III PI3K, hVps34 
[220]. Recently, inhibition of class III PI3K through 3-MA was observed only 
transiently [217]. In a model system of H2O2-toxicity, inactivation of the 
Vps34/phosphatydil-inositol-3-phosphate kinase (PI3K) III signaling pathway, either by 
pharmacologic inhibition with 3-MA or by transgenic expression of a dominant-
negative Vps34, prevented the onset of autophagy and protected dopaminergic 
neuroblastoma cells [221]. In the model system of glutamate toxicity, inhibition of class 
III PI3K activity using siRNA did not protect HT-22 cells (Fig. 14). Additionally, no 
change of the neuroprotective effect of 3-MA against glutamate was observed in class 
III PI3K siRNA treated cells.  
In conclusion, 3-MA mediated neuroprotection against glutamate toxicity is not 
mediated through class III PI3K inhibition, further indicating that autophagy-
independent mechanisms mediated neuroprotection by 3-MA.  
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4.1.4 The PI3K/Akt and the MAPK/Erk-1/2 signaling pathways are not involved 
in 3-MA mediated neuroprotection 
The PI3-K/Akt and the MAPK/Erk-1/2 pathways are the most prominent survival 
signaling cascades that can be stimulated in neurons by a wide variety of cytokines or 
growth factors [189, 201]. In this study, inhibition of class I PI3K and the downstream 
target Akt, was conducted using LY294002. LY294002 did not protect HT-22 cells 
against glutamate and decreased 3-MA mediated neuroprotection against glutamate-
induced toxicity (Fig. 15). At first, this result indicated that 3-MA is a positive regulator 
of the PI3K/Akt pathway. However, this result can also suggest an additive inhibitory 
effect by 3-MA on the PI3K/Akt pathway.  
The investigation of direct effects on p-Akt protein levels in our system revealed that 3-
MA decreased p-Akt levels in the presence and absence of glutamate (Fig. 15 C, D). 
Together, these results demonstrated that 3-MA is rather a negative regulator of the 
PI3K/Akt pathway. Nevertheless, it is unlikely that negative regulation of the PI3K/Akt 
pathway is the main mechanism for 3-MA-mediated neuroprotection. For instance, 
LY924002, which also decreases Akt phosphorylation, was not protective against 
glutamate toxicity (Fig. 15 A, B). This is in line with a large body of evidence showing 
that activation of the PI3K/Akt signaling cascade mediates survival in neurons [222]. 
 
In addition, the MAPK/Erk-1/2 pathway was intensively studied to investigate its 
contribution for pro-survival signaling in different types of cultured cells, including 
neurons. It is well documented that activation of MAPK/Erk-1/2 mediated 
neuroprotection in cultured neurons [223, 224]. The MAPK/Erk-1/2 pathway has also 
been implicated in glutamate-induced oxidative stress in HT-22 cells. U0126, a specific 
inhibitor of the ERK-activating kinase MEK-1/2 protected both HT-22 cells and 
immature primary cortical neuron cultures from glutamate toxicity [225, 226].  
Glutamate was also reported to cause a biphasic activation of Erk-1/2 in HT-22 cells. 
According to these studies, the initial peak of Erk-1/2 activation plays a protective role 
whereas the second peak was caused by prolonged oxidative stress and mediates cell 
death [226].  
In our system, 3-MA transiently enhanced phosphorylation of MAPK/Erk-1/2 within 30 
min (Fig. 16). Erk-1/2 signals declined to control levels already after 1 h. This finding 
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suggested a transient activation of Erk-1/2 by 3-MA. In a pharmacological approach, 
the specific MEK 1 inhibitor PD98059 protected HT-22 cells against glutamate-induced 
oxidative stress, indicating that the underlying mechanism of protection was rather 
dependent on inhibition of the MAPK/Erk-1/2 pathway (Fig. 15). This result is in line 
with a previous study that showed, that MAPK/Erk-1/2 pathway is implicated in 
glutamate-induced oxidative stress HT-22 cells [225]. However, it cannot be excluded if 
the transient activation of Erk-1/2 by 3-MA after 30 min did contribute to 
neuroprotection in the model system of glutamate toxicity in HT-22 cells.  
Further, the AMP-activated protein kinase (AMPK) signaling pathway was investigated 
after 3-MA treatment. Recent studies revealed that AMPK activation is implicated in 
the regulation of neuronal survival and as a key player during ischemic stroke [227]. In 
addition to Akt, AMPK is one of the main regulators of mTOR. In response to increases 
in AMP/ATP ratio, AMPK preserves intracellular energy substrate levels by switching 
off ATP-requiring processes, while switching on ATP-generating catabolic pathways, 
such as autophagy [228].  
AMPK activation may have dual functions in the regulation of neuronal survival [227]. 
AMPK provides neuroprotective effects during transient energy depletion in a model of 
intracellular Ca
2+
-overload, and this effect is partially mediated by the activation of 
neuronal glucose transporter 3 [229]. In contrast, prolonged AMPK activation can lead 
to neuronal apoptosis via the transcriptional activation of the proapoptotic Bcl-2 family 
member Bim [230].  
The results of the present study show that 3-MA decreased AMPK phosphorylation 
transiently (Fig 16), suggesting that the inhibition of the AMPK signaling pathway is 
likely involved in 3-MA mediated neuroprotection in the model system of glutamate 
toxicity in HT-22 cells. Further investigations are necessary, however, to confirm the 
involvement of the AMPK pathway in 3-MA mediated neuroprotection.  
 
Still, the exact mechanisms of 3-MA-mediated neuroprotection in the present model 
system of glutamate-induced oxytosis are currently unknown. Remarkably, induction of 
autophagy and other cellular actions via persistent inhibition of class I PI3K and 
independent of autophagy inhibition were detected after 3-MA treatment. For example, 
autophagy promotion activity of 3-MA was found to be due to its differential temporal 
effects on class I and class III PI3K; 3-MA blocks class I PI3K persistently, whereas its 
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suppressive effect on class III PI3K is transient [217]. Additionally, 3-MA can affect 
glycogen metabolism, lysosomal acidification [70], endocytosis [71, 231] and the 
mitochondrial permeability transition [72]. 3-MA can suppress proteolysis even in 
Atg5-deficient cells, suggesting that 3-MA may have some additional effects on protein 
degradation other than autophagy [48].  
 
4.1.5 Modulation of mitochondrial parameters through 3-MA treatment 
Mitochondria are crucial organelles in every cell as they are the primary source of 
energy, and they are involved in many catabolic and anabolic reactions of different 
metabolites, the regulation of ROS metabolism and calcium homeostasis. In addition to 
their central role in various biochemical pathways, mitochondria are key regulators of 
development, aging and programmed cell death, in particular in neurons [232]. 
Mitochondria are dynamic organelles that undergo permanent fission and fusion under 
physiological conditions. In damaged neurons, however, this dynamic process is 
disturbed leading to excessive fragmentation of mitochondria and thereby promoting 
cell death progression [233–235]. Although the mechanisms controlling mitochondrial 
morphology under pathological conditions are only partly known, increasing evidence 
suggests a potential role for oxidative stress and impaired bioenergetics as potential 
triggers of mitochondrial fission in the cell death program [182]. 
The present study demonstrated that glutamate-induced cell death was associated with 
mitochondrial fragmentation, mitochondrial membrane depolarization, ROS production, 
decreased ATP levels and elevated mitochondrial oxygen consumption (Fig. 18, 19, 20), 
and disturbance of the mitochondrial dynamic balance towards fission. These effects 
were prevented by 3-MA. These data suggested that 3-MA modulated regulators of 
mitochondrial damage that mediate enhanced mitochondrial fission, loss of 
mitochondrial integrity, loss of energy (ATP), increased ROS production, and elevated 
mitochondrial oxygen consumption. The exact link between the major survival 
signaling pathways of 3-MA and mitochondrial signaling in HT-22 cells needs to be 
further elucidated.  
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4.1.6 Conclusion and Outlook 
In summary, the findings of this part of the thesis work demonstrated that glutamate 
activated hallmarks of the autophagy machinery in HT-22 cells during cell death. The 
detected autophagy, however, did not cause cell death and was dispensable for 
execution of oxytosis. As an intracellular mechanism, the observed induction of 
autophagy rather indicated the ultimate attempt to survive by adapting to stress and 
enhancing cellular resilience. Autophagy plays a major role for cellular homeostasis, 
however in the present model system of oxytosis the autophagy induction was 
insufficient to ultimately prevent glutamate-induced cell death.  
Following established protocols, 3-MA was used in the present study as a tool to inhibit 
autophagy in glutamate-induced cell death in HT-22 cells. The results of this thesis 
strongly suggest that 3-MA is not a selective inhibitor of autophagy. In contrast, 3-MA 
mediated its neuroprotective effect against glutamate toxicity in HT-22 cells 
independently of autophagy inhibition. The protective effects of 3-MA were associated 
with the inhibition of PI3K/Akt and the AMPK pathways and transient activation of the 
MAPK/Erk-1/2 signaling pathway. Nowadays, 3-MA is used frequently in experimental 
studies in vivo and in vitro. Based on the present findings, caution is recommended in 
the interpretation of data obtained with 3-MA in the context of autophagy studies, in 
particular, if mitochondrial alterations are connected.  
Due to the importance of autophagy for cellular homeostasis, development and survival, 
and the knowledge that impaired autophagy can contribute to the pathology of various 
diseases, research in the field autophagy is increasing continuously. Besides in vitro and 
in vivo animal studies, first clinical trials were registered recently. To date, 45 clinical 
trials are registered at http://clinicaltrials.gov involving autophagy modulation. In most 
trials the drug hydroxychloroquine is used. Hydroxychloroquine is a drug that has been 
used to treat malaria and rheumatism [236, 237]. It has been recently discovered that 
hydroxychloroquine inhibits autophagy [186]. In the majority of trials different forms of 
cancer are in the focus for investigation. Cancer cells use autophagy to survive 
chemotherapy or hormonal therapy [238]. Also, cancer cells use autophagy to survive in 
areas of a tumor where there is a low oxygen level [239]. Recent medical science 
suggests that it is possible to make anticancer therapy work better if autophagy is 
blocked. The investigators aim to elucidate if blocking autophagy while giving standard 
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treatment for the particular type of cancer will improve the treatment (NCT00933803, 
NCT00765765 and others). Another study focuses on the influence of autophagy in 
nonalcoholic Fatty Liver Disease (NCT01988441). Also, the effect of low protein diet 
to correct defective autophagy in patients with collagen VI related myopathies in Phase 
II was investigated (NCT01438788). No clinical trials were found so far that focused on 
AD, PD or other neurodegenerative diseases that involved the modulation of the 
autophagic process. This is may be attributed to opposing roles of autophagy as a 
regulator of cellular homeostasis and resilience in healthy neural tissue in contrast to 
impaired autophagy as a mechanism of cell death in neurological diseases. For further 
studies, the development of therapeutic strategies will need to take into account these 
opposing roles of autophagy. 
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4.2 Conditioned medium of neuronal cell lines as a therapeutical option for 
neurodegenerative diseases 
Beneficial effects of neuronal progenitor cell (NPC) transplantation have been well 
established in animal models of acute brain damage. Since only very few NPC cells 
survive intracerebral transplantation, enhanced neurogenesis may only play a minor role 
for the observed functional and histological protection of brain tissue. Thus, induction 
of cell death by trophic factor withdrawal was performed in the present study to mimic 
the conditions after neural progenitor cell injection. The CM obtained from this in vitro 
approach should contain the putative protective factors that are also delivered by dying 
NPC in the cellular grafts in vivo. 
Deprivation of growth factors promoted cellular death of NPC that was accompanied by 
caspase-3 activation and PARP cleavage. Cell death of NPC was prevented by the broad 
caspase inhibitor Ovd-OPh. Conditioned medium that was prepared during NPC 
starvation protected HT-22 cells against glutamate-induced neurotoxicity. Further, 
heating of NPC CM abolished the protective effect of NPC CM, indicating that proteins 
were likely responsible for the neuroprotective effect. Apoptotic bodies and also the 
mechanism of autophagy induction play only a minor role for the mediation of 
protective effects of NPC CM. In primary neurons, the most prominent pro-survival 
signaling pathways, namely the PI3K/ Akt pathway and the Erk 1/2 pathway, were 
activated upon NPC CM treatment. In a different approach, CM of HT-22 cells exposed 
to induction of autophagy by spermidine was tested for its ability to mediate 
neuroprotection. It has been shown previously that spermidine induced autophagy, 
which increased life span and showed protective effects in several animal models from 
flies to mice [203]. In the HT-22 cells, spermidine mediated a dose-dependent toxicity, 
but did not mediate protective effects by itself. 3-MA prevented spermidine-induced 
toxicity in an autophagy independent manner. The protective effects mediated by Sp 
CM were not as potent as protection achieved with NPC CM.  
In summary, these data demonstrated that CM of NPC and HT-22 cells mediated 
neuroprotective effects in the model system of glutamate toxicity in PCN and HT-22 
cells. Therefore, conditioned medium could serve as potent therapeutical option to treat 
acute or chronic neurodegenerative diseases that are accompanied by oxidative stress 
and excitotoxicity.  
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4.2.1 NPC conditioned medium mediates neuroprotective effects 
Nowadays, stem cell based therapy represents a powerful new therapeutic option for the 
treatment of neuronal diseases. Stem cells and progenitor cells have the potential to 
enhance neurorestorative processes like neurogenesis, angiogenesis and modulation of 
inflammation or trophic support, thus facilitating functional recovery and 
neuroprotection [128–131].  
In fact, however, most cells die after transplantation in vivo [149] suggesting that the 
beneficial effect after transplantation is rather mediated by released protective and/or 
trophic factors than neuron replacement. In the present study an in vitro model system 
was developed to mimic the conditions of stem/progenitor cell transplantation. The 
NPC were deprived of growth factors, which induced caspase dependent apoptotic cell 
death (Fig. 21). Caspase-dependent apoptotic cell death after serum deprivation was 
already described in mesenchymal stem cells [240] and several other types of stem cells 
suggesting similar mechanisms for serum deprivation-induced cell death in NPC.  
In the present model system of serum deprivation-induced cell death in NPC, Qvd-OPh 
mediated a partial protection (Fig. 23) and prevented the cleavage of caspase-3 and 
PARP (Fig. 22). Active caspase-3 is a key mediator of apoptosis in mammalian cells 
and responsible for the proteolytic cleavage of many key proteins such as caspase-6, -7 
and -9 or the nuclear enzyme PARP [195]. PARP is activated in different paradigms of 
cellular stress, mediating either repair mechanisms or cell death, depending on the 
context and the strength of the stress stimulus. Cleavage of PARP serves as a marker of 
cells undergoing caspase-dependent apoptosis [196].  
Medium from dying NPC (NPC CM) was found to mediate neuroprotection in the 
model systems of oxidative stress and excitotoxicity in neurons (Fig. 24 A, B). 
Moreover, Eva Öxler demonstrated in our laboratory that the rescue of NPC from 
starvation by the caspase inhibitor Qvd-OPh abolished the neuroprotective effect of 
NPC CM [199], indicating that caspase-dependent cell death was essential for 
generating the highly protective NPC CM. 
Previous studies using conditioned medium from a variety of different stem cells also 
demonstrated protective effects. For example, a previous study in our laboratory showed 
that application of adult bone marrow stromal cells (BMSC) CM attenuated 
staurosporine (STS) or amyloid-beta peptide-induced apoptosis and triggered 
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endogenous survival signaling pathways that mediate protection against apoptotic 
insults in primary embryonic rat neurons [154]. Others showed that NSC conditioned 
medium (NSC CM) was neuroprotective in vitro, in a model of Huntington’s disease 
[157]. In another study with human MSCs CM, the authors found that MSCs secrete 
brain-derived neurotrophic factor (BDNF) which promoted neuronal survival in 
cultured rodent cortical neurons against trophic factor withdrawal or nitric oxide (NO) 
exposure [160]. Further, BMSC CM that contained insulin-like growth factor (IGF)-1, 
hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and 
transforming growth factor (TGF)-β1, promoted neuronal survival and neurite 
outgrowth in hippocampal neurons [241]. 
Together, these data suggested that dying NPC secrete substances that protect 
neighboring cells. It turned out that NPC CM is an adequate tool for the investigation of 
the factors and mechanisms mediating protective effects after stem/progenitor cell 
transplantation in vitro.  
 
4.2.2 Characterization of the protective effect of the NPC CM 
The hypothesis that NPC secrete protective factors during cell death led to further 
experiments that focused on the analysis of the composition of the NPC CM and the 
related mechanisms of protection. During the previous characterization process of 
BMSC CM [154], heating over 90°C abolished the neuroprotective effect of BMSC 
CM, suggesting that heat labile factors, i.e. proteins, released by BMSC mediated the 
observed anti-apoptotic effect in the neurons. In mammalian cells, enzymes and proteins 
show a functional optimum around 35-40°C and they denature if exposed to 
temperatures higher than 60°C. During denaturation, proteins lose their quaternary, 
tertiary and secondary structure, which typically results in the loss of their biological 
function. The loss of biological function is irreversible, if the protein cannot regain its 
native state when the denaturing influence is removed. The thermostability of proteins 
depends on various factors such as amino acid composition, hydrophobic interactions, 
ion pairing or hydrogen bonds within the protein [242]. Heat exposed NPC CM (95°C 
for 30 min) no longer protected HT-22 cells in the model of glutamate-induced 
neurotoxicity (Fig. 26). This result clearly indicated an involvement of proteins for NPC 
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CM mediated neuroprotection, which was further confirmed in our laboratory by Eva 
Öxler [199]. 
 
Apoptotic bodies have been demonstrated to enhance the differentiation of human 
endothelial progenitor cells in vitro [198]. Isolated apoptotic bodies that were obtained 
after serum deprivation-induced cell death in NPC did not mediate neuroprotection 
[199]. Further, Y-27632, which blocks the formation of apoptotic bodies, did not affect 
the protective effects of CM against glutamate-induced toxicity. However, treatment 
with Blebbistatin revealed a decrease in the protective effect of NPC CM, indicating 
that apoptotic bodies may partly participate in NPC CM mediated neuroprotection.  
To test the specificity of NPC CM, mouse embryonic fibroblast CM (MEF CM) was 
compared to NPC CM in the model system of glutamate toxicity in HT-22 cells. MEF 
CM was much less protective than regular NPC CM indicating that neuronal progenitor 
cells are necessary for the production of potent CM (Fig. 25). Additionally, Eva Öxler 
found that also CM prepared from HT-22 cells and other neuronal stem cell lines 
mediated neuroprotective properties during starvation [199], which approved that the 
protective effect is specific for neuronal cells or stem/progenitor cells.  
Prosurvival signaling pathways linked to CM-mediated neuroprotection are the 
PI3K/Akt and the MAPK/Erk-1/2 pathway. The PI3-K/Akt and the MAPK/Erk-1/2 
pathways are important survival signaling cascades that can be stimulated in neurons by 
a variety of cytokines or growth factors [189, 201]. As a proto-oncoprotein and the 
primary target of PI3K, Akt was first characterized for its function in regulating cell 
survival and cell proliferation in neurons [222]. Constitutive activation of Akt signaling 
is sufficient to block cell death induced by a variety of apoptotic stimuli [243]. It was 
already described that also activation of MAPK/Erk-1/2-mediated neuroprotection in 
cultured neurons [223, 224] and in models of cerebral ischemia in vivo [244, 245].  
In the primary neurons, phosphorylation of Akt and Erk-1/2 increased within 10 min up 
to 120 min after exposure to NPC CM (Fig. 28). These findings implicated that NPC 
secrete neuroprotective factors that may stimulate neurotrophin-like survival signaling 
thereby contributing to the protective effects against growth factor withdrawal and 
glutamate neurotoxicity. This assumption was supported by size exclusion filtration 
experiments that indicated that the components of CM mediating the neuroprotective 
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effect have a molecular size between 10 and 50 kDa [199]. Growth factors like BDNF, 
VEGF, EGF or FGF have a molecular weight between 6 kDa and 27 kDa. However, it 
is conceivable that also substances with another molecular weight may contribute to or 
reinforce the potency of NPC CM. Also the finding that proteins are likely responsible 
for the mediation of neuroprotection of NPC CM support the hypothesis that growth 
factors or neurotrophins participate in the survival signaling of NPC CM. Heating of 
NPC CM to 95°C abolished its neuroprotective effect (Fig. 26). Though, heating of 
NPC CM to 50-80°C further increased the protective effect against glutamate-induced 
neurotoxicity [199]. This thermostability was so far not demonstrated for growth 
factors. Moreover, the recombinant growth factor BDNF did not protect HT-22 cells 
against glutamate toxicity, because HT-22 cells do not express functional TrkB 
receptors [246]. Further, MALDI TOF analysis revealed that NPC CM did not contain 
growth factors like BDNF, VEGF, EGF, FGF or NGF. So far, Peroxiredoxin-1 and 
galectin-1 were found that are jointly responsible for mediating neuroprotection [199].  
 
4.2.3 Autophagy induction does not contribute to the protective effect of NPC 
CM 
Autophagic activity is essential for numerous physiological processes, including cell 
survival, cell metabolism, development, aging and immunity, and is generally 
considered to mediate cell survival [12]. Starvation is the best characterized inducer of 
autophagy [58]. Here, starvation of NPC was achieved by growth factor deprivation 
leading to caspase-dependent apoptotic cell death. This process was accompanied with a 
clear increase of autophagic activity (Fig. 29). Inhibition of autophagy with 3-MA did 
not protect NPC against EBSS-induced starvation, indicating that starvation did not 
induce autophagic cell death. NPC CM that was prepared with 3-MA still protected HT-
22 cells against glutamate- induced toxicity (Fig. 30), which indicated that the process 
of autophagy was not essential for the mediation of neuroprotection through NPC CM.  
So far, the mechanisms underlying the neuroprotective effect of NPC CM are not fully 
understood and are matter of ongoing studies.  
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4.2.4 Spermidine conditioned medium is not neuroprotective in the model system 
of glutamate toxicity 
However, the induction of autophagic activity by starvation in NPC was not essential 
for the protective effect of NPC CM in the model system of glutamate-induced 
oxidative stress, spermidine was used to induce autophagy selectively in HT-22 cells. 
The aim was to investigate, if the preparation of spermidine conditioned medium (Sp 
CM) mediated neuroprotective effects that were dependent on autophagy activation.  
Spermidine (Sp) is a ubiquitous polycation that is synthesized from putrescine and 
serves as a precursor of spermine. Putrescine, spermidine and spermine are polyamines 
that play a role in multiple biological processes. Spermidine has recently been shown to 
promote longevity across species in an autophagy-dependent manner [203, 247]. The 
regulatory mechanism underlying this effect might be of epigenetic origin. In yeast, 
spermidine inhibits the activity of histone acetyltransferases and leads to a global 
hypoacetylation of histone H3 at all acetylation sites spanning the N-terminus of the 
histone. Thus, the promoter of the ATG7 gene required for autophagy is hyperacetylated 
after post-treatment with spermidine. These results support that spermidine activates a 
global transcriptional response which may involve epigenetic regulation [247]. 
Genetic inactivation of genes essential for autophagy abolishes the life span-prolonging 
effect of spermidine in yeast, nematodes and flies [248]. Additionally, spermidine 
improved both survival and locomotor activity of the fruit fly Drosophila melanogaster 
upon exposure to paraquat [204]. Simple spermidine feeding not only restored juvenile 
polyamine levels, but also suppressed age-induced memory impairment [249].  
These findings complement expanding evidence that autophagy mediates cytoprotection 
against a variety of noxious agents and can confer longevity when induced at the level 
of the whole organism.  
In HT-22 cells, spermidine induced an increase of LC3-II accumulation (Fig. 31), 
indicating activation of autophagy also in the presently used system of neuronal cells. 
Dose-dependent cell death after the challenge of spermidine was prevented with 3-MA 
(Fig. 32), but not with siRNA targeting key regulators of autophagy, namely Beclin-1 
and Atg5 (Fig. 33), which further proves the theory that autophagy is rather protective 
than detrimental to cells. 
In the present study, subtoxic concentrations of spermidine, which were previously 
reported to promote longevity and mediate both survival and locomotor activity of the 
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fruit fly Drosophila melanogaster upon exposure to the superoxide generator and 
neurotoxic agent paraquat [204], could not mediate neuroprotection in the model system 
of glutamate-induced oxidative stress (Fig. 35 A). This result suggested that spermidine 
has various functions in different cell types independent or dependent of autophagic 
activity. With the preparation of Sp CM, the aim was to investigate, if autophagy 
activation in HT-22 cells leads to the release of neuroprotective substances. Spermidine 
CM prepared with low concentrations of spermidine did not mediate protection (Fig. 
35), indicating that sole activation of autophagy to release protective substances out of 
the cell into the medium is simply not enough to promote survival. 
As outlined before, results obtained from NPC CM experiments revealed that cell death 
of NPC was necessary to obtain conditioned medium that promoted neuronal survival 
[199]. However, Sp CM obtained from dying HT-22 cells did not protect cells against 
glutamate induced toxicity or spermidine toxicity, and it was only protective in the 
control groups in comparison to the regular spermidine treatment (Fig. 36). In 
conclusion, Sp CM prepared from dying cells exerted only moderate effects, but was at 
least more potent than Sp CM from HT-22 cells that were alive. This weak 
neuroprotective effect of Sp CM is likely due to cell death of the HT-22 cells which 
released protective factors and, therefore, this effect is unlikely specific for spermidine 
treatment. Therefore, autophagy can rather be excluded as the mediator of 
neuroprotection. Additionally, Eva Öxler already demonstrated that CM from HT-22 
cells that underwent starvation was protective against glutamate toxicity [199]. 
Although starvation and spermidine treatment led to cell death, the CM obtained from 
these two processes act differently in the model system of glutamate toxicity. A 
problem of Sp CM might be that it was not possible to remove spermidine from CM. 
Attempts were made to remove spermidine from CM with cut off filtration experiments 
(Milipore, 3kDA filter). Unfortunately spermidine accumulated in the concentrate of the 
filter, likely due to interactions with the membrane of the filter tube. The filtrate was not 
protective and the concentrate was toxic, likely because spermidine accumulated in the 
supernatant and that was further accompanied by a strong pH elevation.  
In addition to the life span-prolonging effects, improved survival and locomotor activity 
and suppression of age-induced memory impairment of PAs in several in vitro model 
systems, recent findings demonstrated that PAs were also involved in the direct or 
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indirect regulation of programmed cell death (PCD). Direct correlation of PAs with cell 
death refers to their association with particular biological processes, and their physical 
contact with molecules or structures involved in cell death. Indirectly, PAs regulate 
PCD through their metabolic derivatives, such as catabolic and interconversion 
products. Cytotoxic products of PA metabolism are involved in PCD cascades, whereas 
it remains largely elusive how PAs directly control pathways leading to PCD [250]. 
Caspase-dependent and independent apoptotic cell death was already observed after 
treatment with several PA analogues [251]. PAs could contribute directly to PCD 
through their regulatory effect on ion channels. For example, spermine directly 
regulates acid sensing anion channels on neurons that are involved in PCD induction 
[252]. Surprisingly, both activation and prevention of apoptosis due to PA depletion are 
reported for several cell lines, but also elevation of PA levels may lead to apoptosis or 
to malignant transformation [253]. In mammals, the PA-dependent PCD perhaps 
involves mitochondrial dysfunction. Polyamine oxidation results in mitochondrial 
dysfunction and related intrinsic cell death pathways [254, 255].  
So far, PA treatment was not regularly used as a model system to induce neurotoxicity 
in HT-22 cells. Therefore, further experiments aimed on the investigation of the 
molecular mechanism of spermidine toxicity in HT-22 cells. Dose-dependent cell death 
after the challenge of spermidine was caspase-independent and Bid-independent and 
could be prevented with 3-MA treatment (Fig. 32), but not with siRNA targeting key 
regulators of autophagy, namely Beclin-1 and Atg5 (Fig. 33), which further proves the 
theory that autophagy is rather protective than detrimental to HT-22 cells.  
Thus, the exact mechanism of spermidine mediated cell death requires further studies 
that should evaluate how spermidine mediates neurotoxicity. 
 
4.2.5 The final aim: clinical use of NPC CM 
The results of this thesis expose CM from dying NPCs as a viable and promising tool 
for the treatment of neurodegenerative insults, which could bypass several technical and 
clinical limitations of direct stem/progenitor cell transplantation. Stem cell 
transplantation holds risks for severe long-term effects, such as severe immune 
responses or tumor formation. To date it remains unknown, which type and number of 
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stem cells are the most suitable regarding safety and efficacy, and which is the optimal 
route of delivery for therapeutic approaches in neurodegenerative diseases. For that 
reason it is highly important to ensure safety of stem and progenitor cell transplantation 
and to develop alternative strategies such as the application of stem cell conditioned 
medium that may overcome risks and limitations of classic stem cell therapy. Further 
analysis of NPC CM to identify as much components as possible could be the basis for 
the development of a highly potent, standardized composition for the therapy of 
neurodegenerative diseases.  
The neuroprotective benefit of CM as well as safety, uniformity and reproducible 
generation, and the exact application of CM have to be tested in extensive studies in 
vivo before transferring this therapeutic concept to patients in clinical trials. First in vivo 
experiments using the CM in animal models of ischemic brain damage are already 
conducted in collaboration with Nikolaus Plesnila (Department of Neurosurgery, 
University of Munich Medical Center Grosshadern, Ludwig-Maximilians University, 
Munich, Germany) and Klas Blomgren (Department of Pediatric Oncology, The Queen 
Silvia Children's Hospital, University of Gothenburg, Sweden). First in vivo 
experiments were performed in a neonatal mouse model of hypoxia/ischemia (HI) with 
highly concentrated NPC CM. Experiments started at post natal day (PND) 9, with a 
NPC CM pretreatment, followed by hypoxic ischemia. Short term evaluation was 
executed after PND 10, long term evaluation started after PND 40 with behavior tests, 
such as open field test (a locomotion activity and anxiety test) and rearing test 
(exploratory activity and emotionality test). First positive and significant results showed 
that NPC CM was neuroprotective in an in vivo hypoxia model system. 
These results from this promising in vivo study support the conclusion that NPC CM 
could serve as therapeutical option for the treatment of acute or chronic 
neurodegenerative diseases in human patients. The NPC CM may be further developed 
into a drug that could be applied systematically, stored and used ‘off the shelf’ which is 
impossible for stem cells. Depending on the cause of the disease and the related 
therapeutic time window, the cells producing therapeutic CM could be even obtained 
from the very same patient through generation of inducible pluripotent stem cells from 
fibroblasts or hair follicle cells of the patient. 
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4.3 Conclusion: Mechanisms of cell death such as autophagy and apoptosis 
can contribute to neuronal survival 
The aim of this thesis was to investigate the role of two different, but well investigated 
cell death mechanisms, namely autophagy and apoptosis, in the model system of 
glutamate toxicity in cultured neurons.  
Autophagy was found to act as an intracellular mechanism contributing to cellular 
survival and intracellular homeostasis in HT-22 cells. Induction of lethal stress led to 
activation of autophagy, but autophagy did apparently not contribute to the execution of 
cellular death. Thus, the observed induction of autophagy is interpreted as the ultimate 
attempt of the neural cells to adapt to lethal stress.  
In the system of starvation-induced apoptosis in NPC, cellular death led to the 
preparation of a conditioned medium that mediated potent neuroprotective effects at the 
cellular level in model systems of glutamate toxicity. Induced apoptosis via starvation 
released substances that were neuroprotective, demonstrating that apoptotic cell death 
was required to mediate neuroprotection of other cells and possibly for entire organs in 
a whole organism. The preparation of conditioned medium in vitro mimicked the 
process of stem cell transplantation in vivo. Adult stem cells that contribute to 
neurogenesis and stem cells that are transplanted in case of neurodegenerative diseases 
contribute to neuronal survival and can improve brain functions. Nevertheless, these 
cells also die after transplantation and disappear after a few weeks. This finding 
indicated that the results obtained from the in vitro model system in this thesis are 
transferable to the adult organism, as recently confirmed in a model of neonatal 
hypoxia-ischemia in mice. 
For future studies on autophagy and apoptosis it could be interesting not to contemplate 
both mechanisms as isolated mechanisms or to link them solely to cellular demise. 
Recent studies strongly indicated that a crosstalk between autophagy and apoptosis 
exists. The mechanisms linking autophagy and apoptosis are not fully understood. 
However, recent publications have revealed that several pro-apoptotic proteins (e.g., 
PUMA, Noxa, Nix, Bax, XIAP, and Bim) modulate autophagy. Moreover, autophagic 
proteins that control nucleation and elongation regulate intrinsic apoptosis through 
calpain- and caspase-mediated cleavage of autophagy-related proteins, which switches 
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the cellular program from autophagy to apoptosis. Similarly, several autophagic 
proteins are implicated in extrinsic apoptosis [256]. The crosstalk between autophagy 
and apoptosis has also been associated with trauma (e.g., haemorrhage and sepsis) 
[257], AD [258], HIV infection [259], and neural damage [246]. Although apoptosis is 
the major mechanism of cell death in these disease processes, autophagy plays dual 
roles by mediating cell death or cytoprotection, and, the latter may also apply for 
apoptosis, depending on the context of tissue damage and cellular stress. Elucidating the 
mechanisms underlying the connection between autophagy and apoptosis in these 
diseases may be useful for the development of targeted treatments as well as 
considering both mechanisms also contributing to cellular resilience. 
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5 Summary  
Autophagy and apoptosis play major roles in determining the cellular fate. Accordingly, 
they participate in development, cellular homeostasis, and both in physiological as well 
as in pathological processes. Apoptosis is executed by activated caspases, which are 
specific enzymes that participate in signaling cascades that culminate in the rapid 
removal of organelles and other cellular structures. Autophagy is a highly conserved 
cytoprotective process whereby cytoplasmic contents are sequestered, transported via 
double-membrane autophagosomes to lysosomes, and degraded. Along with regulated 
necrosis and other forms of programmed cell death, pathological mechanisms of 
autophagy and apoptosis have been detected in neurodegenerative diseases, such as 
Parkinson’s disease or Alzheimer’s disease and acute brain injuries.  
The aim of this thesis was to investigate the role of autophagy and apoptosis for 
neuronal resilience versus neuronal cell death in model systems of glutamate toxicity in 
vitro.  
 
The role of autophagy was investigated in the model system of glutamate-induced 
oxidative stress, i.e. oxytosis in neural HT-22 cells. The objectives were to determine 
the effect of oxidative glutamate toxicity on autophagic flux and to investigate if 
oxytosis involves autophagy pathways of cell death. Moreover the neuroprotective 
effect of 3-Methyladenine (3-MA), a widely used autophagy inhibitor, was explored in 
the model systems of glutamate-induced oxytosis and excitotoxicity in neural HT-22 
cells and primary cortical neurons, respectively. 
Glutamate clearly enhanced autophagy markers and induced cell death in HT-22 cells 
and PCN. Cell death was prevented by 3-MA, a widely used inhibitor of autophagy. 
Interestingly, 3-MA itself induced autophagy in HT-22 cells. A gene silencing approach 
targeting key regulators of autophagy reduced the autophagic flux, but failed to prevent 
cell death persistently. 3-MA prevented the glutamate-induced ROS formation, the loss 
of ATP, and preserved the mitochondrial membrane potential as well as mitochondrial 
morphology. The activation of the PI3K/Akt pathway and the MAPK/Erk-1/2 pathway 
do not play a role in 3-MA mediated neuroprotection.  
In conclusion, these data suggest that glutamate toxicity is associated with increased 
markers of autophagy. However, specific gene silencing of key regulators of autophagy 
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did not provide protective effects, suggesting that the increased autophagic flux was 
dispensable for cell death induced by glutamate. The induction of autophagy can rather 
be interpreted as the ultimate attempt to adapt to lethal stress after glutamate challenge 
und is rather prosurvival and contributes to cellular homeostasis in HT-22 cells. Further, 
the findings clearly demonstrate that protective effects by 3-MA occur independently of 
autophagy inhibition, although the compound is widely used as an inhibitor of 
autophagy. Nowadays, 3-MA is used frequently in experimental studies in vivo and in 
vitro. Based on the present findings, caution is recommended in the interpretation of 
data obtained with 3-MA in the context of autophagy studies, in particular, if 
mitochondrial alterations are connected.  
 
The contribution of apoptosis to neuronal survival through intercellular signaling 
between dying cells and neurons was investigated using conditioned medium of neural 
progenitor cells (NPC) and HT-22 cells. Stem cells as well as progenitor cells have been 
widely used in model systems of neurodegenerative diseases and acute brain injuries 
where transplantation of these cells into the brain improved neuronal survival and brain 
functions in experimental settings. However, most transplanted cells die after 
transplantation in vivo, and the exact mechanism of action of stem cell or progenitor cell 
transplantation still remains unknown. To investigate mechanisms of intercellular 
signaling underlying the protective effects of transplanted stem cells, the transplantation 
conditions were mimicked in vitro by preparation of conditioned medium (CM) 
obtained from dying neuronal progenitor cells. This CM should contain similar cellular 
components as released during cell death of the progenitor cell transplants, and this CM 
should therefore also provide neuroprotective effects. Thus, the CM of dying/apoptotic 
cells was applied in model systems of cell death in vitro for to test its potential to 
mediate neuroprotection. Further, the composition of the conditioned medium obtained 
from the dying progenitor cells was analysed for identifying the most potent protective 
components that may be applied as neuroprotectants in vitro and in vivo instead of the 
CM or the cellular transplants. 
In order to mimic the conditions of transplantation, NPC were exposed to medium 
lacking growth factors such as FGF and EGF. Such growth factor deprivation induced 
caspase-dependent cell death in NPC in a time-dependent manner. The conditioned 
medium obtained from apoptotic NPC significantly attenuated cell death induced by 
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growth factor withdrawal and glutamate exposure in HT-22 cells and cortical neurons in 
a dose-dependent manner. The protective effect of NPC CM against glutamate 
neurotoxicity was abolished by heat inactivation at 95°C for 30 min. Further, NPC CM 
enhanced phosphorylation of PKB/Akt and Erk 1/2 in neurons in a similar time frame as 
the neurotrophin BDNF. Inhibition of autophagy did not diminish the protective effect 
of NPC CM. Also the use of spermidine conditioned medium (Sp CM) from HT-22 
cells, whose production aimed on the specific activation of autophagy, indicated that the 
induction of autophagy is not essential for the protective effect of conditioned medium.  
In total, these findings suggest that NPC secrete neuroprotective factors that stimulate 
neurotrophin-like survival signaling thereby providing protective effects against growth 
factor withdrawal and glutamate neurotoxicity. The results obtained from the in vitro 
model system in this thesis are transferable to the adult organism. Thus, the results are 
the basis for the development of a highly potent, standardized composition for the 
therapy of neurodegenerative diseases and acute brain injury. Therefore, CM and its 
active components could serve as an alternative therapeutic option to stem cell 
transplantation. 
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6 Zusammenfassung 
Autophagie und Apoptose sind hochregulierte, komplexe Mechanismen, die eine 
bedeutende Rolle in der Entwicklung, Funktion und Homöostase von Zellen und 
Geweben eines Organismus einnehmen. Apoptose ist durch die Aktivität spezifischer 
Enzyme, der Caspasen, gekennzeichnet, die festgelegte programmierte Signalkaskaden 
in Gang setzten, was u.a. einen schnellen Abbau von Organellen und anderen zellulären 
Strukturen zur Folge hat. Autophagie ist ein hoch konservierter und in der Regel 
protektiver Prozess, bei dem zytoplasmatische Bestandteile in so genannte 
Autophagosomen eingeschlossen und transportiert werden und schließlich in den in 
Lysosomen degradiert werden. Bei neurodegenerativen Erkrankungen, wie Morbus 
Parkinson, Morbus Alzheimer und akuten Gehirnerkrankungen sind in den letzten 
Jahren zunehmend auch Mechanismen der Autophagie und Apoptose detektiert worden. 
Diese Befunde führten zu der Schlussfolgerung, dass bei diesen Erkrankungen die 
erhöhte Aktivität von Apoptose und Autophagie zum fortschreitenden Zelltod der 
Neurone und dem progressiven Verlust der Hirnfunktionen essentiell beitragen.  
 
Das Ziel dieser Arbeit war es daher, die möglichen Funktionen von Autophagie und 
Apoptose in Modellsystemen von Glutamat-Toxizität in kultivierten Neuronen in vitro 
zu untersuchen, um die Rolle dieser Mechanismen beim neuronalem Zelltod zu klären. 
Die Rolle von Autophagie wurde im Modellsystem von Glutamat-induziertem 
oxidativem Stress in neuronalen HT-22 Zellen untersucht. Eine Zielsetzung war, den 
Effekt von oxidativer Glutamat-Toxizität auf die Aktivierung von Autophagie-
Mechanismen in den Neuronen zu bestimmen und so zu klären, ob und in welchem 
Ausmaß hier Autophagie zum  Zelltod beiträgt. Zudem wurde in Modellsystemen der 
Glutamat-Toxizität auch der neuroprotektive Effekt des vielfach verwendeten 
Autophagie-Inhibitors 3-Methyladenin (3-MA) untersucht. 
In HT-22 Zellen und primären kortikalen Neuronen (PCN) war die Glutamat-induzierte 
Toxizität von einem deutlichen Anstieg von Autophagie-Markern begleitet. Der 
Glutamat-induzierte Zelltod wurde durch den Autophagie-Inhibitor 3-MA signifikant 
vermindert. Allerdings induzierte 3-MA selbst Autophagie in HT-22 Zellen. Im 
Gegensatz dazu gelang es nicht, die Zellen mit Hilfe von genetischer Regulation der 
Autophagie gegen die Glutamat-Schädigung zu schützen. Die siRNA-vermittelte 
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Expressionshemmung von Schlüsselregulatoren der Autophagie reduzierte zwar 
erwartungsgemäß die autophagische Aktivität, war aber nicht in der Lage, den Zelltod 
dauerhaft aufzuhalten. Der Inhibitor 3-MA verhinderte zudem die Glutamat-induzierte 
Bildung von reaktiven Sauerstoffspezies und den Verlust von ATP, wobei sowohl das 
Mitochodrienmembranpotential als auch die mitochondriale Morphologie erhalten 
blieben. Die Aktvierung der PI3K/Akt- und der MAPK/Erk-1/2 Signalwege sind 
offenbar nicht an der 3-MA vermittelten Neuroprotektion beteiligt. 
Schlussfolgernd zeigen diese Daten, dass Glutamat-Toxizität mit einer Aktivierung der 
Autophagie einhergeht. Allerdings lieferte die siRNA-vermittelte spezifische Hemmung 
der Expression von Schlüsselregulatoren der Autophagie keine protektiven Effekte, so 
dass die gemessene autophagische Aktivität nicht entscheidend zum Glutamat-
induzierten Zelltod beiträgt. Die Induktion von Autophagie ist in diesem 
Zusammenhang offenbar eine Gegenregulation der Zellen, über die eine Anpassung an 
den Stress vermittelt wird. In den untersuchten Neuronen trägt die Autophagie eher zum 
Überleben und zur zellulären Homöostase bei und ist nicht als Mechanismus des 
Zelltodes zu verstehen. Weiterhin zeigen die Ergebnisse, dass der protektive Effekt von 
3-MA in den Mitochondrien der Neurone unabhängig von einer Inhibition der 
Autophagie erfolgt, obwohl die Substanz vielfach als Inhibitor der Autophagie 
verwendet wird. Basierend auch auf den vorliegenden Ergebnissen sind also Daten, die 
mit 3-MA in Autophagiestudien erhoben werden, zurückhaltend zu interpretieren, 
insbesondere dann, wenn mitochondriale Schädigungen den Zelltod vermitteln.  
 
Der Beitrag von Apoptose zu neuronalem Überleben durch interzelluläre Signale 
zwischen sterbenden (Stamm) Zellen und Neuronen wurde in Modellen des 
Nährstoffentzugs in neuronalen Vorläuferzellen und im Glutamat-Schädigungsmodell in 
den HT-22 Zellen untersucht. Therapeutische Effekte von Stammzellen und neuronalen 
Vorläuferzellen sind in Modellsystemen von akuten und chronischen 
neurodegenerativen Erkrankungen umfangreich nachgewiesen worden. In 
experimentellen Studien steigerten beispielsweise entsprechende Zelltransplantate das 
neuronale Überleben und die Erhaltung und Regeneration von Gehirnfunktionen. 
Jedoch sterben die meisten Zellen nach der Transplantation in das Gehirngewebe 
schnell ab und auch der exakte Mechanismus der therapeutischen Effekte von solchen 
Zelltransplantationen ist bislang weitgehend unbekannt. Die vorliegende Arbeit 
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untersuchte, inwieweit das Absterben von neuronalen Vorläuferzellen für die 
beobachteten protektiven Effekte von transplantierten Zellen von Bedeutung ist. Zu 
diesem Zweck wurden die Transplantationsbedingungen in vitro nachgeahmt indem aus 
dem Medium von neuronalen Vorläuferzellen (NPC) die Wachstumsfaktoren EGF und 
FGF entfernt wurden, um so apoptotischen Zelltod zu induzieren. Das konditionierte 
Medium von diesen apoptotischen Zellen sollte ähnliche zelluläre Komponenten 
enthalten, die auch nach der Transplantation von den sterbenden Stamm- oder 
Vorläuferzellen im Gehirn in vivo freigesetzt werden und die möglicherweise die 
neuroprotektiven Effekte vermitteln. Das konditionierte Medium der apoptotischen 
neuronalen Vorläuferzellen wurde im Modell der Glutamatschädigung in HT-22 Zellen 
auf neuroprotektive Effekte untersucht. Weiterhin wurde die Zusammensetzung des 
konditioniertem Mediums der sterben Progenitorzellen analysiert, um die wirksamsten 
protektiven Komponenten zu identifizieren, die dann vielleicht in vitro und in vivo an 
Stelle des konditionierten Mediums oder zellulärer Transplantate appliziert werden 
könnten. 
Der Wachstumsfaktorentzug induzierte in den NPC einen Caspase-abhängigen Zelltod. 
Das konditionierte Medium (CM) von den apoptotischen NPC zeigte deutliche 
dosisabhängige protektive Effekte und verhinderte in HT-22 Zellen und kortikalen 
Neuronen den Zelltod nach Wachstumsfaktorentzug und Glutamatbehandlung. Der 
protektive Effekt des konditionierten Mediums wurde durch Hitzeinaktivierung bei 
95°C für 30 Minuten aufgehoben. Weiterhin verstärkte das CM die Phosphorylierung 
von Erk 1/2 und PKB/Akt in primären Neuronen in einem ähnlichen Zeitrahmen wie 
das Neurotrophin BDNF. Autophagieinhibition in NPC schwächte die beschriebene 
neuroprotektive Wirkung nicht ab. Konditioniertes Medium, das von den NPC nach 
Induktion von Autophagie durch Spermidin gewonnen wurde, zeigte keinerlei 
protektiven Effekte in dem Modell der Glutamat-Schädigung in HT-22 Zellen. Die 
Aktivierung von Autophagie in NPC ist also im Gegensatz zur Apoptose offenbar nicht 
ausreichend, um protektive Faktoren zu bilden und in das konditionierte Medium 
abzugeben.  
Zusammenfassend deuten diese Ergebnisse deuten darauf hin, dass apoptotische NPC 
neuroprotektive Faktoren sezernieren, die neurotrophin-ähnliche Überlebenssignalwege 
stimulieren und so protektive Effekte gegen Nährstoffentzug und Glutamat-Toxizität 
vermitteln. Die Resultate des in vitro Modellsystems in dieser Arbeit sind übertragbar 
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zum adulten Organismus. Die vorliegenden Erkenntnisse sind die Basis für die 
Entwicklung einer zellfreien, standardisierten und potenten neuroprotektiven 
Komposition, die eine Alternative zur Stammzelltransplantation darstellt und neue 
therapeutische Optionen für die zukünftige Behandlung von akuten und chronischen 
neurodegenerativen Erkrankungen bieten kann. 
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8 Abbreviations 
3-MA    3-Methyladenine 
AD    Alzheimer´s disease 
AIF    Apoptosis inducing factor  
ALS    Amyotrophic lateral sclerosis 
AMP    Adenosine monophosphate 
AMPA    α-amino-3-hydroxy-5-methylisoxazole-4-propionate 
AMPK    5' Adenosine monophosphate-activated protein kinase 
ANOVA    Analysis of variance 
Apaf-1    Apoptosis protease-activating factor-1 
ATP    Adenosinetriphosphate 
BCA    Bicinchonic acid 
Bcl-2     B-cell lymphoma-2 
BDNF    Brain-derived neurotrophic factor 
bFGF    basic Fibroblast growth factor 
BMSC    Bone mesenchymal stem cells 
BODIPY    4,4-Difluoro-5-(4-phenyl-1,3-butadienyl)- 4-bora-  
    3a,4a-diaza-sindacene-3-undecanoic acid 
BSA    Bovine serum albumin  
CAD    Caspase-activated deoxyribonuclease 
CCCP    2-[2-(3-Chlorophenyl)hydrazinylyidene]propanedinitrile 
CM    Conditioned medium 
CMA    Chaperone- mediated autophagy 
CNS    Central nervous system 
CQ    Chloroquine 
CVEC    Coronary venular endothelial cell 
CYTC    Cytochrome C     
DAPI    4',6-Diamidino-2-phenylindole 
DMEM    Dulbecco’s Modified Eagle Medium 
DMSO    Dimethyl sulfoxide 
DNA     Desoxyribonucleic acid 
DTT     DL-Dithiothreitol 
EBSS    Earle's Balanced Salt Solution 
EDTA     Ethylenediaminetetraacetic acid 
eEF 2    eukaryotic Elongation factor 2 
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EGF    Endothelian growth factor 
EGTA  Ethylene glycol-bis (2-aminoethylether)-N,N,N´,N´- tetraacetic 
acid 
ENDOG   Endonuclease G 
ESC    Embryonic stem cell 
FACS    Fluorescence activated cell sorting 
FasL     Fas-ligand 
FCCP    Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
FCS     Fetal calf serum 
FGF    Fibroblast growth factor 
Gal-1    Galectin-1 
Gpx4    Glutathion peroxidase 4 
GSH     Glutathione 
H2O2    Hydrogen peroxide 
HBSS    Hank’s Balanced Salt Solution 
HD    Huntington´s disease 
hNSCs    Human neural stem cells 
HRP    Horseradish peroxidase 
IAP    Inhibitor of apoptosis protein 
IGF    Insulin growth factor 
iNCs    induced neuronal cells 
iNSCs    induced neural stem cells 
IP3    Inositol trisphosphate 
iPSCs    induced pluripotent stem cells 
KA    Kainic acid 
LC3     Microtubule- associated protein light chain 3 
LY294002   2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
MAPK    Mitogen-activated protein kinase 
MCAO    Middle cerebral artery occlusion 
MEF    Mouse embryonic fibroblast 
MEK     Mitogen activated protein kinase kinase  
MMP    Mitochondrial membrane potential 
MOMP    Mitochondrial Outer Membrane Permeabilization 
MSCs    Mesenchymal stem cell 
mTOR    mammalian target of Rapamycin 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
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NaOH    Sodium hydroxide 
NF-κB    Nuclear factor κB 
NMDA    N-methyl-D-aspartic acid 
Noxa    Phorbol-12-myristate-13-acetate-induced protein 1 
NPC    Neural progenitor cell  
NSCs    Neural stem cells 
OCR     Measurement of cellular oxygen consumption rate 
Omi/HtrA2    High temperature requirement protein A2 
PA    Polyamine 
PAR    Poly (ADP-ribose) 
PARP-1   Poly (ADP-ribose) polymerase 1 
PBS     Phosphate buffered solution 
PCD    Programmed cell death 
PD    Parkinson´s disease 
PE     Phosphatidylethanolamine  
PFA    Paraformaldehyde 
PI3K     Phosphoinositide-3-kinase  
PIP2    Phosphatidylinositol (3,4)-bisphosphate 
PIP3    Phosphatidylinositol (3,4,5)-triphosphate 
PKC    Protein kinase C 
PLA 2    Phospholipase A 2 
PND    Post natal day 
Prdx    Peroxiredoxin 
PSCs    Pluripotent stem cells 
PUMA    p53 upregulated modulator of apoptosis 
PVDF    Polyvinylidenfluorid 
Qvd-OPh N-(2-Quinolyl) valyl-aspartyl-(2,6-difluorophenoxy) methyl 
ketone   
RIP 1,3    Receptor interacting protein 1,3 
RMS    Rostral migratory stream 
ROS    Reactive oxygen species 
SDS    Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SGZ    Subgranular zone 
siRNA    Small interfering ribonucleic acid 
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SMAC/DIABLO  Second mitochondria–derived activator of caspase/direct IAP 
binding protein with low pI 
STS    Staurosporine 
SVZ    Subventricular zone 
TBE    Tris/borate/EDTA 
TBI    Traumatic brain injury 
tBid    truncated Bid 
TBST    Tris-buffered solution with Tween 20 
TEMED    Tetramethylenethylendiamin 
TMRE     Tetramethylrhodamin ethyl ester 
TNFR    Tumor necrosis factor receptor 
TSC 1,2   Tuberous sclerosis protein 1,2 
VEGF    Vascular endothelian growth factor 
xCT    Glutamine-cystine antiporter 
XIAP    X-chromosomal linked inhibitor of apoptosis 
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9 Publications 
9.1 Original papers 
J Neurosci Methods. 2012 Jan 15;203(1):69-77. Epub 2011 Sep 22. Impedance 
measurement for real time detection of neuronal cell death. Diemert S, Dolga AM, 
Tobaben S, Grohm J, Pfeifer S, Oexler E, Culmsee C. 
In preparation: 3-Methyladenine mediates neuroprotection against glutamate toxicity in 
HT-22 cells independent of autophagy inhibition. Neunteibl S., Dolga A. M., Elsaesser 
K., Culmsee C. 
 
9.2 Oral presentations and posters 
Selected talks: 
Oral presentation for the abstract “Preconditioned medium from neuronal progenitor 
cells provides neuroprotective effects” presented at the 51th Jahrestagung der Deutschen 
Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie 
(DGPT), 2010, Mainz, Germany. 
Selected abstracts and poster presentations: 
Pfeifer, S., Dolga, A.M., Engel, S., Culmsee, C. (2009) Neuronal progenitor cells 
provide trophic support and protection against glutamate-induced neurotoxicity, DPhG 
Jena, 2009 
S. Pfeifer, A.M. Dolga, S. Engel, C. Culmsee, Preconditioned medium from neuronal 
progenitor cells provides neuroprotective effects. 51
th
 Jahrestagung der Deutschen 
Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie 
(DGPT), 2010, Mainz, Germany. 
S. Diemert, S. Pfeifer, J. Grohm, S. Tobaben, A.M. Dolga, C. Culmsee Real-time 
detection of neuronal cell death by the xCELLigence system. 51
th
 Jahrestagung der 
Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und 
Toxikologie (DGPT), 2010, Mainz, Germany. 
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A.M. Dolga, J. Grohm, S. Pfeifer, S. Tobaben, C. Culmsee, (2010) Activation of small 
conductance KCa2 channels prevents neuronal death induced by delayed calcium 
deregulation, 11th Meeting of the European Calcium Society, Warsaw, Poland 
Pfeifer, S., Dolga, A.M., Engel, S., Blomgren, K., Culmsee, C. (2010) Conditioned 
medium of neural progenitor cells protects neuronal cells against growth factor 
withdrawal and glutamate-induced neurotoxicity, Society for Neuroscience Annual 
Meeting , Neuroscience 2010, San Diego, USA, 11.2010 
Culmsee C., Pfeifer S., Dolga A.M., Blomgren K., Öxler E.M. Life from death: 
Apoptotic neural progenitor cells protect neurons against growth factor withdrawal and 
glutamate toxicity. Society for Neuroscience Annual Meeting, Neuroscience 2012, New 
Orleans, USA, 13.10.2012-17.10.2012  
Öxler E.M., Pfeifer S., Dolga A.M., Blomgren K., Culmsee C. “Phoenix rising”: The 
potential of apoptotic neural progenitor cells to provide neuroprotection. Fraunhofer 
Life Science Symposium, 29.11.2012-30.11.2012, Leipzig, Germany  
 
9.3 Patent 
Patent No. 12166390.0 - 2107, Culmsee C. Blomgren K., Pfeifer S., Öxler E.M., Sato 
Y., Zhu C., Stem cell derived composition for the treatment of acute injury and 
degenerative diseases, date of filing 02.05.2012 
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